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ABSTRACT 
 
Background: The introduction of Antiretroviral Therapy (ART) and especially Highly Active 
Antiretroviral Therapy (HAART) has led to an improvement in both quality and length of life 
among patients with HIV/AIDS. However, studies have shown that HAART requires adherence 
levels of 95% and above in order to achieve therapeutic success. Sub-optimal adherence, which  
has been associated with  treatment failure and emergence of drug resistant HIV strains, has been 
cited as a major concern with the scaling up of ART programs in resource limited sub-Saharan 
Africa. Thus monitoring adherence rates and identifying factors that influence adherence to 
HAART are essential components of HAART programmes. However, since the inception of the 
programme in 2003, no studies have been conducted in Namibia to measure the adherence or 
identify factors that affect adherence among the patients on HAART. 
 
Aim: To obtain baseline data on adherence levels and the major determinants of adherence 
among patients on HAART at Rundu Hospital, Namibia.  
 
Methodology:  A cross-sectional descriptive study of adult patients on first line HAART 
regimen attending Rundu Hospital, Namibia, was conducted. An administered structured 
questionnaire was used to collect data on the socio-demographic characteristics, adherence rates 
and magnitude of barriers and facilitators of adherence among patients on HAART.  
Three adherence measuring strategies were used: 2 day recall, 30 day self report and pill counts. 
Data was analysed using Epi-info (CDC, 2004) programme and means, medians, standard 
deviation, range and frequency distribution were computed for the variables. Mean adherence 
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levels and the proportion of patients achieving adherence levels of 95% and above were 
measured. Adherence was analysed categorically as dichotomous:  optimal (>or = 95%) and sub 
optimal (< 95%) and also as three categories:  high (> or = 95%), medium (85 - < 95%) and low 
(< 85%).  Association between adherence as the outcome variable and predictor variables was 
tested using prevalence ratio and Chi squared test, or Fischer exact tests when expected cell size 
was less than 5. 
 
 Results:   Seventy-eight percent of the 97 participants included in the study were female, 
resulting in a female to male ratio of 4 :1. The mean age of the participants was 36.7 (SD: 9.00) 
years with 80% of the participants being in the 20-44 age group. The mean duration on ART 
treatment was 20 (SD: 10.3) months with 76% of the participants being on ART for 24 or less 
months. The average adherence rate reported by mean composite of the three measures was 
95.1%, while the proportion of patients who achieved adherence levels of 95% and above was 
64%.  The main barriers to adherence to HAART reported by participants were forgetfulness 
(28%), lack of food (13%) and being away from the pills (11%): facilitators reported included 
counselling (19%) and treatment supporters (11%). Having knowledge of the consequences of 
failing to take HAART as prescribed was significantly associated with adherence (p = 0.03), as 
was being female (p = 0.04) while living further than 6 km from the hospital was significantly 
associated with non adherence (p = 0.018).  
 
Conclusion:  The adherence rates reported in this study indicate an urgent need to design 
intervention measures to enhance adherence among patients on HAART in this setting.   
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CHAPTER 1   
1. INTRODUCTION 
1.1 BACKGROUND 
Human Immunodeficiency Virus (HIV), which leads to Acquired Immunodeficiency 
Disease (AIDS,) continues to present major challenges to medical practitioners, public 
health practitioners and even development policy makers. The prevalence of the disease 
continues to increase and it was estimated that over 33 million people were living with 
HIV globally in 2007 with 68% of these in sub-Saharan Africa (UNAIDS, 2008).  
 
The introduction of Antiretroviral Therapy (ART) and especially Highly Active 
Antiretroviral Therapy (HAART) has led to an improvement in both the quality and 
length of life of patients with HIV/AIDS (Pallela et al, 1998). Ironically, these drugs have 
not been accessible to most patients in sub-Saharan Africa where more than 79% of 
global AIDS deaths occurred in 2005 (UNAIDS 2006).   
 
However, global advocacy, availability of generic drugs and drug price reductions have 
resulted in increased access to ARTs in low and middle income countries in recent years 
with an estimated 1.3 million people in these resource poor settings gaining access to 
treatment by December 2005 (WHO, 2006). 
 
Adherence to treatment is considered the most important determinant for therapeutic 
success of HAART.  Studies have indicated that a minimum adherence level of 95% is 
required for viral suppression and consequent improved immunologic response (Paterson 
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et al, 2000). The consequences of sub-optimal adherence are treatment failure and 
emergence of drug resistant strains of HIV that that would require more complex and 
expensive treatment regimens (Bangsberg et al, 2001). The emergence of  HIV drug 
resistant strains and the consequent requirement of expensive second line drugs would 
not only impact on access to ARTs,  but would also result in negating  the established and 
intended  cost benefits of scaling up of ART provision in sub- Saharan Africa. This 
premise is also supported  by  Gill, Hamer, Simon, Thea & Sabina (2005) , who point out 
that  the need  for adherence monitoring and support in sub-Saharan Africa is   greatly 
underscored by the  increasing access to ARTs  in  sub- Saharan Africa and  the large 
number of people whose disease  would progress  with sub optimal adherence  in the 
region. 
 
Namibia is situated in south western Africa and is one of the fourteen countries that 
comprise the Southern African Development Community (SADC). In 2007, Namibia had 
a population of 2.0 million people with an estimated 230,000 people, living with 
HIV/AIDS and approximately 61% of them women (UNAIDS, 2008). A sentinel survey 
on pregnant women attending antenatal clinics in 2006, reported a HIV prevalence rate of 
19.9% (MOHSS, 2007b). The same survey reported the highest age- specific prevalence 
ratio as being among those aged 30 to 34 years.  
 
The Ministry of Health and Social Services in Namibia, launched the Anti Retroviral 
Treatment Programme  in six public health facilities in 2003 and the national target was 
that, 30,000 people would be on HAART by 2008  (MOHSS, 2004: UNAIDS,2008). 
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However,  a UNAIDS Report   published in 2008 , showed  that, by December 2006, over 
30,000 people with advanced HIV infection, 66% of them women, were receiving free  
antiretroviral therapy from the 34 public hospitals in Namibia (UNAIDS, 2008). This is 
an illustration of the rapid scaling up of the ARV program in Namibia.  According to the 
same UNAIDS Report, 84% of the patients who enrolled for the HAART Programme  
were alive and still on treatment, 5% had died, 2% had defaulted and 9% were unknown. 
These reported outcomes underscore the need for programme monitoring as more 
patients are enrolled for HAART in Namibia.  
 
In 2003, Namibia produced and adopted National Guidelines for Anti – retroviral therapy 
(MOHSS, 2003).  These guidelines outline: provider, regimen and health related 
measures to promote and ensure continuous adherence to HAART. The guidelines also 
outline the social criteria which the patients should meet so as to be eligible for HAART 
in Namibia. Similarly, the guidelines recommend ongoing patient education and 
continuous monitoring of adherence among patients on HAART.  
 
However, from 2003 to date, no official studies on adherence levels or factors affecting 
adherence have been conducted in Namibia. Thus, since the introduction of ART in the 
public health sector in 2003, there is no baseline data on adherence levels or   the 
correlates of adherence to ART in Namibia.  
 
Rundu Hospital, which is situated in North Eastern Namibia, is the setting of this study. 
Rundu Hospital was one of the six sites that started the provision of ART in Namibia in 
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2003. The ART Programme commenced at Rundu Hospital in September 2003 and by 
May 2007, about 1300 patients were registered on HAART at the hospital. 
Approximately 10% of these were lost to follow up and the adherence levels of the 
remaining 90% were unknown (MOHSS, 2007a).  In addition the factors affecting 
adherence to HAART among these patients on HAART have not been determined. This 
highlights a gap in the monitoring of the programme as measuring levels of adherence 
and identifying correlates of adherence is essential for promoting interventions that 
ensure continuous optimal adherence among patients on HAART.  
 
This study aims to obtain baseline data on adherence levels and the factors that affect 
adherence among adult patients on HAART at Rundu Hospital. This information could 
then be used to develop practical interventional strategies to enhance adherence among 
patients on HAART at this hospital. 
  
1.2. SUMMARY  
In this report, literature on the challenges of measuring adherence, achieving optimum 
levels of adherence and identifying the correlates of adherence among patients on 
HAART in a resource limited setting, will be reviewed. Then, the aims and the objectives 
and the methodology used for the study will be outlined.  Thereafter, the results obtained 
from the study will be presented and discussed. Finally, the conclusion and 
recommendations from the study will be presented.  
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CHAPTER 2 
LITERATURE REVIEW 
Adherence to long term therapy has been a topic of research for more than three decades 
(Yach, 2003, as cited by WHO, 2003 a). However, the introduction of Antiretroviral 
Therapy (ART) and especially Highly Active Antiretroviral Therapy (HAART) has 
pushed treatment adherence into a high priority agenda for medical and behavioural 
researchers. The challenges of HAART are the requirement of “near perfect” adherence 
in a complicated regimen involving long term treatment , with suboptimal adherence 
being associated with treatment failure and emergence of HIV drug resistant strains 
(Chesney, 2000: Patterson et al, 2000 : Bangsberg et al 2001).  The emergence and 
transmission of a drug resistant virus would require more expensive drug regimens and 
impact negatively on the established and intended benefits of ART programmes 
especially in sub- Saharan Africa where the scaling up of ART programs is considered 
essential to counter the devastating effects of HIV/AIDS in the region (Harries et al, 
2001). 
 
In this chapter, the main concepts of the study which were: importance of adherence in 
HAART, measurement of adherence, adherence levels in sub - Saharan Africa and 
correlates of adherence are reviewed.  
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2.1 ADHERENCE AND HAART 
Adherence  has been  defined  as “… the extent to which a person’s behaviour – taking 
medication, following a diet and or executing lifestyle changes corresponds with agreed 
recommendations from a health care provider ...”( Sabate, 2001,  as cited by WHO, 
2003a:18). Adherence therefore encompasses the concept of an informed patient actively 
and accurately participating in a plan of care. 
 
HAART is a multidrug regimen, composed of different classes of ARV drugs, whose 
goal is maximal and durable viral suppression, and restoration of immune response so as 
to halt the progression of AIDS. According to WHO recommendations, HAART   
normally consists  of two nucleoside reverse transcriptase inhibitors (NRTI), a non 
nucleoside reverse transcriptase inhibitor (NNRTI) and, or a protease inhibitor (PI)  
(WHO, 2003b). Currently in Namibia, recommended first line regimens consist of a 
combination of two NRTIs and a NNRTI while second line regimens replace the NNRTI 
with a PI (MOHSS, 2003). The NRTIs currently used for first line treatment are 
lamivudine, stavudine, zidovudine and tenofovir while NNRTIs used are nevirapine and 
efavirenz and the PI used is boosted lopinavir. 
 
 HAART, therefore, is a complicated regimen which has proven to be efficacious in 
inhibiting HIV replication and consequently reducing HIV associated morbidity and 
mortality (Chesney, Morin & Sherr, 2000). However, to achieve these treatment benefits, 
an unprecedented high level of adherence for an indefinite time period is required 
(Boden, Hurley& Zang, 1999: Rabkin & Chesney, 1999).  
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The direct association between adherence to HAART and viral suppression has been 
confirmed by studies whereby sub optimal adherence is associated with poor virological 
and immunological responses characterized by progression to AIDS, detectable viral 
loads and low CD4 cell counts. For instance, Patterson et al, (2000),   in a prospective 
observational study involving HIV infected patients on Protease Inhibitor therapy, 
reported that in patients with adherence rates of   95% and above, only 22% had 
virological failure in contrast with 61% in the patients with adherence rates of 80-94%. 
 
Similarly, findings from a cross-sectional analysis of HIV positive homeless patients on 
Protease Inhibitor therapy showed that none of the individuals with adherence levels 
greater than 90% progressed to AIDS while 38% and 8% of those with adherence rates of 
greater or equal to 50% and 51-89% respectively progressed to AIDS (Bangsberg et al, 
2001). Common to these two studies is the use of protease inhibitors which raises the 
question whether the 95% optimal adherence rate is also required in other HAART 
treatments. 
 
However, in a prospective  cohort study over 12 months of HIV infected patients on 
HAART treatment  involving  both protease inhibitor therapy and non protease inhibitor 
therapy, Mannheimer, Friedland, Matts, Child  & Chesney (2002), reported  a strong 
association between HAART adherence,  virologic suppression and immune recovery. In 
this study, the percentage of patients with undetectable viral loads at 12 months was 66%, 
47% and 17% among the groups with 100%, 80-99% and 0-79% adherence rates 
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respectively. Similarly, the mean increase in CD4 cell count was 179, 159 and 53 cells 
/mm³ among the groups with 100%, 80-99% and 0-79% adherence rates respectively. 
 
Although these studies do not fully define effective adherence levels, they highlight the 
relationship between adherence and treatment outcomes and suggest that adherence levels 
of near 100% are critical in order to achieve   treatment benefits with HAART, 
irrespective of the regimen.  
 
2.2. MEASUREMENTS OF ADHERENCE 
The studies mentioned above suggest that a high level of adherence to treatment is 
required to achieve the full treatment benefits of HAART which include prevention of 
viral resistance, reduced destruction of CD4 cells, maximum and durable suppression of 
viral replication and slowed disease progression.  This relationship between adherence 
and treatment outcomes underscores the need to measure adherence in clinical settings.  
 
2.2.1. STRATEGIES USED TO MEASURE ADHERENCE  
Adherence is an individual, complex and dynamic human behaviour presenting unique 
challenges which make accurate measurement very difficult. While adherence can be 
ensured by direct observed treatment, this is impractical in regimens involving more than 
once daily doses and lifelong treatment like HAART. Consequently, adherence behaviour 
is measured using   indirect methods. Currently, there is no gold standard to measure 
adherence to HAART, thus a variety of strategies are employed. Surrogate markers that  
are used to quantify adherence include plasma drug level monitoring,  electronic drug 
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monitoring,  patient self reports, pill counts and pharmacy records (Vitolins et al ,2000: 
Bangsberg et al 2001: Liu et al,2001) 
 
Plasma drug level monitoring measures the drug concentration in the blood to ascertain 
whether the patient has ingested the drugs. The limitations of this method include the lack 
of indication of the time the drug was taken and the fact that other factors like plasma 
binding, affect plasma drug levels. Another limitation is the cost involved which would 
influence the use of this method in resource limited settings.  
 
Electronic drug monitoring involves an electronic device being fitted to pill containers 
which record the time and date when the medication bottle is opened. Thus removal of 
the cap provides a proxy for the removal of a dose (Bangsberg et al, 2001). However, this 
method is expensive and makes the assumption that recorded bottle openings represent 
actual pill ingestion which could result in overestimation of adherence.  
 
Pharmacy records are used to monitor prescription refills whereby collecting the 
medication on the due date is assumed to be adhering to treatment. This strategy is 
considered an objective approach to quantify adherence and due to its low cost, it is a 
practical method in resource limited settings (Nachega et al, 2006). However, for 
pharmacy records to be an effective proxy of adherence, an effective record system is 
essential and may require the use of only one pharmacy for refills. A limitation of this 
method is the assumption that prescription refilling corresponds to taking medication 
which could again result in overestimation of adherence.   
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Pill counts are another method used to assess adherence. Pills are counted after a certain 
period and the excess pills considered evidence of non adherence. Pill counts can either 
be announced whereby the patient is aware that the pills will be counted on a specific 
day: or unannounced whereby pill counts are done without prior warning (Liu et al, 
2001). Unannounced pill counts may reduce pill dumping which is a limitation generally 
associated with this approach. Pill counts are a strategy that is considered objective and 
also inexpensive thus making it favourable in resource limited settings. However, it is 
labour intensive especially in a clinical setting and the assumption that the missing pills 
were ingested could result in overestimation of adherence. 
 
Self report involves the patient reporting on their adherence behaviour. The tools used to 
collect information include questionnaires and visual analogue scales. Questionnaires are 
used to ask the patients on their adherence behaviour for instance on specific days. A 
visual analogue scale is a measurement instrument that tries to measure a characteristic 
that ranges across a continuum of values (Crichton, 2001). For the measure of adherence, 
a patient is asked to report on their adherence behaviour using a scale, for instance a line 
marked 1 to 10 (Walsh, Mandalia & Gazzard, 2002). In the current study, the visual 
analogue scale used was a container with beads marked with a scale of 1 to 10. The beads 
represented the pills that were supposed to be taken in a month and   the participants were 
asked to empty beads that represented the pills they had ingested in the last 30 days, and 
thereafter, the remaining beads were then measured using a line scale of 1 to 10. A 
similar visual analogue scale was used in an ART adherence study in Tanzania (Irunde, 
Temu, Maridadi, Nsimba & Comoro, 2006). Self report as a strategy has the advantage of 
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low cost, ease of administration and can help to determine reasons why patients fail to 
adhere, which increases the strategy’s practicability in resource limited settings. However 
it is vulnerable to recall bias and social desirability and therefore tends to overestimate 
adherence.  
 
2.2.2. CHALLENGES   OF MEASURING ADHERENCE   
The challenge to accurately assess adherence in both clinical and research settings is   
demonstrated by studies that use different adherence measuring strategies. In most of 
these studies, the HIV viral load is  used as an external criteria, whereby the strength of 
association between viral load and the surrogate measure is used to demonstrate construct 
validity of the individual measure (Grossberg, Zhan & Gross,2004: Fairley, Permane & 
Read,2005).  
A study by Arnsten, Demas, Grant, Gourevitch, Farzedegan & Howard (2001) compared 
self report and electronic drug monitoring and found adherence levels of 79% with self 
report in contrast to only 53% by electronic drug monitoring. The study further validated 
these findings through viral loads whereby it was found that patients whose electronic 
drug monitoring data indicated adherence levels of more than 90% were more likely to 
achieve undetectable viral loads than patients self reporting the same level of adherence.  
 
A similar study by Liu et al (2001) concurrently compared three measures of adherence 
to HAART against patients’ undetectable viral load rates. The study found mean 
adherence levels of 63% (SD 0.31) by electronic drug monitoring, 83% (SD 0.17) by pill 
count and 93% (0.14) by self report. Moreover, the mean difference in adherence 
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between patients who had detectable viral loads and those with undetectable viral loads 
after  8  weeks were  statistically significant using  electronic drug monitoring (p = 0.02) 
and   using  pill counts (p = 0.01) but  were not statistically significant when using  self 
report (p > 0.2). Findings from these studies showed a lack of correspondence between 
the different adherence measures and undetectable viral loads which suggested 
overestimation of adherence by these adherence measures.   
   
However, the choice of strategy is often influenced by financial and logistic factors. For 
instance, despite the tendency to overestimate adherence, self report is the most 
commonly used method in both resource rich and resource constrained settings,  due to 
ease of administration and low cost. This popularity is observed in  a  meta analysis by 
Mills et al (2006 a) which reported 71% of North American studies and 66%  of sub - 
Saharan African studies included in the meta-analysis used self report to measure 
adherence.  
 
An observation from the same meta-analysis is the use of multiple measures to assess 
adherence by 6% of North American included studies and 22% of sub - Saharan African 
studies. In the present study, three adherence measures were used to assess adherence:  2 
day self report, 30 day report using a visual analogue scale and pill counts. Multiple 
strategies to measure adherence have been used in studies to ensure accuracy of 
adherence estimates as strengths of one method compensate for the weaknesses of the 
other while at the same time collecting  data on different dimensions of adherence (Liu et 
al 2001: Arnsten, et al, 2001). Multiple measures to assess HAART adherence, similar to 
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those used in the current study, have been validated in studies conducted in sub-Saharan 
Africa (Oyugi et al, 2004:  Steel, Nwokike & Joshi, 2007). Thus the use of multiple 
measures in this study was aimed at increasing the accuracy of the reported adherence 
levels.  
 
2.2.3. MEASURES OF ADHERENCE LEVELS   
Considering the importance of adherence in HAART, adherence should be monitored at 
both individual and programme levels thus two measures are frequently used to report 
adherence to HAART. The first one records adherence as the proportion of doses taken 
correctly and is reported as the mean adherence level of a given population while  the 
second reports the proportion of the patients taking at least 95% of their HAART 
medication correctly which reflects adherence on a programme level.  
 
Thus the first measure is an indication for the clinical evaluation of individual patients 
which is relevant for counselling purposes. The second measure, on the other hand, is a 
population measure and therefore is essential for programme evaluation and planning.  
Laing & Hodgkin (2006), argue that both adherence levels, which are collected using the 
same strategies, should be used as outcome measures. This is  on the premise  that 
average adherence levels may appear high, but if  only a fraction of users are achieving 
optimal adherence , there is still a danger of poor health outcomes for most of the ART 
users.  
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An illustration of this discrepancy is a cross-sectional study by Irunde et al (2006) in 
Tanzania, which reported a mean adherence rate of 90%. However, only 21% were 
reported to have achieved adherence levels of 95% and above. Thus despite high mean 
adherence levels, most of the patients were not obtaining the full benefits of their 
treatment.  
 
 Thus, in addition to improving access to ARVs to more patients living with HIV/AIDS 
in sub - Saharan Africa, ART programme goals should also include achieving and 
sustaining optimal treatment outcomes.   
 
Evolving evidence shows that the relationship between adherence levels and virologic 
suppression varies among different classes of ARVs. Indeed emerging data indicates that 
ARV classes may have different adherence relationships with some classes manifesting 
virus  resistance at low adherence levels and others at high to moderate adherence levels 
(Walsh et al , 2002: King,Brun,Tschampes,Mosley &Kempf, 2003). This additional 
dimension in adherence levels indicates that categorizing adherence  purely into optimal 
and sub optimal levels is not adequate as further exploring of adherence is required in 
order to understand the dynamics of the different components of HAART. Accordingly, 
adherence should be categorized into high, medium and low levels during statistical 
analysis. Bangsberg, Moss & Deeks (2004) propose that categorizing adherence this way 
facilitates the exploring of patients’ adherence behaviour. Thus analysing adherence in 
this categorization may be useful in studies aimed at designing interventions to support 
adherence to HAART as is the case with the present study.   
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2.3. ADHERENCE LEVELS IN SUB -SAHARAN AFRICA  
The consequences of sub optimal adherence to HAART have both individual and public 
health implications (Chesney, 2000). For the individual, drug resistance and emergence 
of resistant strains would result in an uncertain prognosis and the requirement of more 
toxic and complex drugs. From a public health perspective, the emergence and 
transmission of a drug resistant virus would not only impact negatively on the benefits 
intended by the ART programmes but would  also result in increasingly more people 
requiring more expensive drugs thus increasing the costs of the ART programme. This 
public health perspective has been a major concern on the impact and feasibility of 
increasing accessibility of  HAART to more patients in resource limited sub- Saharan 
Africa (Harries et al, 2001: Liechty & Bangsberg,2003).  
 
This concern however, is not supported by studies conducted so far. Indeed, studies seem 
to suggest that adherence may be higher in sub- Saharan Africa than in developed 
countries (Weiser et al, 2003: Orrel, Bangsberg, Badri & Wood 2003: Nachega et al, 
2004). Similarly, findings from a meta analysis by Mills et al (2006a) involving 37 
studies conducted in North America and 27 in sub - Saharan Africa reported significantly 
higher levels of ART adherence in sub - Saharan Africa  compared to North America  (p 
< 0.001). The meta analysis, which controlled selection bias by including only studies 
that involved mixed populations so as to best reflect the general populations in the 
respective regions, reported an estimate of  55% (95% CI 49% - 62%) of  North 
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American ART users achieving optimal adherence compared to 77%  (95% CI 68% -
85%) of sub - Saharan African ART users. 
 
 Though these findings suggest that more patients were achieving adequate levels of 
adherence in sub- Saharan Africa, it should be noted that these patients who were in early 
treatment programmes, may have been on uncomplicated regimens and with early access 
to limited therapy regarded ART as a precious resource unlike their North American 
counterparts. Other studies conducted in sub - Saharan Africa have shown that adherence 
reduces with time (Laurent et al, 2002: Akam, 2004). These observations support the 
hypothesis by Gill, Hamer, Simon, Thea & Sabina (2005) that maintaining these high 
adherence levels in sub- Saharan Africa may prove to be challenging with time and the 
increasing access to ART by patients living with HIV/AIDS.  
 
With increasing accessibility to ART in sub - Saharan Africa, a number of studies have 
been conducted in routine health settings similar to this study. For instance, a cross-
sectional study by Nwokike (2005) used 7 day recall self report and pill count to measure 
adherence in 176 participants receiving free ART from a general hospital in Botswana. 
The study reported an average adherence rate of 83%, however, only 57.4% patients had 
achieved adherence levels of 95% and above.  
 
In contrast, another cross-sectional study in Botswana, involving 514 ART users in four 
district hospitals reported that 77% (95% CI 73.1 – 80.9) patients had achieved adherence 
levels of 95% and above. The study which used  2 day self report, 30 day recall using a 
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visual analogue and  pill counts to measure adherence in ART users in four district 
hospitals in Botswana also reported a mean adherence rate of 94% (Kgatlwane , Ogenyi , 
Ekezie,  Madaki,  Moyo,  & Moroka, 2006).  
 
In Zambia, a cross-sectional study used pill counts and pharmacy records to measure 
adherence among 424 patients receiving HAART at a rural hospital and reported that 
83.7% of the patients achieved adherence levels of 95% and above (Carlucci et al, 2008).  
 
These studies show that adherence levels in sub - Saharan Africa vary which underscores 
the need to measure adherence as more patients gain access to HAART in the region. The 
focus of these studies was quantification of adherence rates and identification of 
facilitators and barriers of adherence which were similar to the aims of the present study. 
Similarly, the use of low cost multiple measures of adherence to obtain more accurate 
adherence levels in these resource limited settings were pertinent to this study. However, 
due to high cost, viral load testing was not routinely performed on ART patients in 
resource limited settings thus lack of validation of reported adherence levels with viral 
loads was a limitation in these sub- Saharan African studies and also in this study.  
 
2.4. CORRELATES OF ADHERENCE  
While adherence is important in any treatment, the critical nature of high levels of 
adherence HAART in order to achieve the treatment benefits have already been 
emphasized (Boden, Hurley, Zang, 1999: Patterson et al, 2000). Hence having a clear 
understanding of both the barriers and facilitators of adherence will assist clinicians in 
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identifying patients who need assistance with their pill taking and to design and evaluate 
interventions that enhance adherence. Several studies have classified barriers to 
adherence into the following categories: as related to patient, regimen, disease and the 
health care system variables (Murphy, Roberts, Martin, Marelich & Hoffman, 2003: 
Powell-Cope, White, Henkelman & Turner, 2003).   
 
2.4.1. PATIENT VARIABLES  
Patient variables comprise socio-demographic factors and psychosocial issues. Socio-
demographic factors include age, gender, education level and economic status while 
psychosocial factors include mental illness such as   history of substance abuse or 
depression, social support, knowledge and beliefs about HIV (Chesney, Ickovics, 
Chambers, 2000 : Murphy, Wilson, Durako, Muenz & Belzer, 2001).   
 
Some, studies conducted in developing countries show that other socioeconomic factors 
seem to affect adherence to HAART. Mills et al (2006 b), in a systematic review of 84 
studies on patient reported factors affecting adherence in both developed and developing 
settings, lists financial constraints and insufficient knowledge about HAART as barriers 
to adherence in developing nations.  
 
Financial constraints have also been reported as barriers in other studies in sub- Saharan 
Africa (Weiser et al, 2003; Ndayanga et al, 2004: Akam, 2004). These financial costs are 
mostly related to transport costs to the hospital and food costs rather than the costs of 
buying the ARVs. Transport costs were also reported as barriers of adherence in recent 
 
 
 
 
19 
 
studies in Rwanda, Uganda and Botswana (Mukabatera, et al, 2004:  Nakiyemba et al, 
2006:  Kgatlwane et al, 2006).  
 
Beliefs and knowledge about HIV have also been associated with adherence to ARVs. 
Studies included in the systematic review by Mills et al (2006 b) report difficulties in 
understanding both the treatment instructions and the importance of adherence in 
HAART, as barriers to adherence in developing nations. In addition, difficulties in 
understanding  the importance of adherence in HAART, may be linked to having  
insufficient knowledge on HAART that was reported as a barrier to adherence in studies 
in Burkina Faso and Rwanda (Traore et al, 2004: Mukabatera et al, 2004).   
On the other hand, knowledge on HIV and HAART may also be linked with beliefs 
which impact on adherence. For instance, use of alternative treatments to HIV, was   
reported to be associated with non adherence in studies in sub - Saharan Africa (Eholie et 
al, 2004:  Ndayanga et al, 2004: Akam, 2004). This may be due to lack of belief in the 
effectiveness of HAART that may be a result of having insufficient knowledge on HIV or 
HAART.    
 
Other patient characteristics that have been associated with adherence to HAART are age 
and gender but these have not been consistent across studies. For instance Diabate, Alary 
& Koffi (2007), in a prospective study in Cote d’Ivoire reported that being older than 35 
years was associated with non adherence. However, another study in Nigeria reported 
that female gender was associated with adherence but found no significant association 
between adherences and age (Abah et al, 2006).   
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Stigma and disclosure of HIV status are other patient characteristics that have been 
associated with non adherence in studies across Sub - Saharan Africa (Mukabatela, 2004: 
Nakiyemba, et al, 2006). A study in South Africa by Nachega et al, (2004), reported that 
fear of stigmatization by sexual partners was associated with non adherence. Stigma and 
disclosure are closely linked as patients may not disclose their status for fear of 
stigmatization by family members or the community which could result in lack of social 
support and consequently non adherence.    
 
2.4.2. REGIMEN CHARACTERISTICS   
HAART involves a regimen of three or more ARVs, resulting in a complicated regimen 
that is also lifelong (Chesney, Morin & Sherr, 2000). These regimens involve a high pill 
burden of different drugs that require either different timing of doses or different food 
requirements. These are all factors that could contribute to non adherence. However, the 
more recent introduction of fixed doses has greatly reduced the pill burden as two or 
sometimes three drugs are incorporated in one pill (Oyugi et al, 2004).  
 
Other regimen characteristics that might affect adherence are dosing schedules for 
instance Patterson et al (2000) reported that twice daily doses were associated with better 
adherence than three times daily dosing. Adherence levels were found to be higher with 
certain ARV combinations within the same study in Senegal and Botswana (Laniece et al, 
2003: Nwokike, 2005). This could be due to different dosing schedules among the drugs 
in an ARV combination. For instance one ARV combination may have drugs that require 
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twice daily dosing and others that require once daily dosing which would complicate the 
combination and lead to non adherence. 
 
These  multiple daily doses may sometimes be accompanied by extensive toxicity and 
side effects which further influence the patient’s ability and willingness to adhere to 
HAART (Chesney, 2000: Orrell et al ,2003). HAART is associated with a range of 
different side effects, some of which are temporary like nausea while others may be 
longer lasting like lipodostrophy. However, a number of studies have reported that the 
occurrence of side effects did not affect adherence to HAART (Weiser et al, 2003: 
Nakiyemba et al, 2006). This may suggest that the individuals’ perception of the need for 
medication in relation to its adverse effects largely depends on that individual’s context. 
 
2.4.3   DISEASE CHARACTERISTICS  
The stage and duration of HIV infection, severity of symptoms, level of disability, rate of 
progression of disease and opportunistic infections could all potentially impact on 
adherence to HAART. Whilst, there has been inconsistent findings regarding CD4 cell 
count and clinical stage of HIV as correlates of adherence (Amassari et al, 2002: Orrell et 
al, 2003), little is known of the effect of other disease factors on adherence. 
 
In Namibia, the recommendations are  to commence HAART in HIV positive patients 
with  a CD4 cell count of less or equal to 200cells/mm³, irrespective of the WHO staging  
or WHO AIDS clinical stage 3 or 4 irrespective of the CD4 cell count (MOHSS, 2003). 
The existence of other clinical conditions like tuberculosis is common among these 
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patients which in turn affect the clinical condition of the patient (MOHSS, 2007a). Such 
co- morbidity determines the choice of regimen for the patient and also increases the pill 
burden which might further impact on adherence.  
 
2.4.5.   HEALTH CARE SYSTEM VARIABLES  
Health care system variables include patient- provider relationship and the specific 
characteristics of the health care setting. Studies in resource limited settings have 
identified health care settings as an important factor in adherence to ARVs. 
 
For instance, intervals of more than 6 months between medical visits and insufficient 
medical counselling were found to be barriers to adherence in patients initiating HAART 
in Brazil (Bonolo et al, 2005). Counseling was also associated with adherence to HAART 
in some studies in sub - Saharan Africa. For instance, adherence partners and pharmacy 
adherence counseling were reported as adherence promoters in Botswana (Nwokike, 
2005). Similarly, the number of counseling sessions before commencing HAART was 
identified as a predictor of adherence in Uganda (Muganzi, Bondo, Drana & Biryeni, 
2004). Counselling impacts on patients’ knowledge and information on HIV and HAART 
which could address some patient variables like beliefs, regimen characteristics like 
dealing with side effects and disease characteristics such as opportunistic infections. In 
addition, adherence supporters provide some level of social support which could help 
address stigma and disclosure issues while also acting as reminders to enhance 
adherence. 
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Other health care systems issues including long distances to hospitals, long waiting times, 
insufficient counselling on HAART and lack of confidentiality in health facilities were  
also identified as barriers to adherence to HAART in studies in sub - Saharan (Irunde et 
al , 2006: Nakiyemba  et al,  2006). Similarly, long distances to health facilities were also 
identified as a barrier to adherence to HAART in Botswana, (Weiser et al, 2003:  
Kgatlwane et al, 2006). Long distances to hospital and long waiting times are issues 
associated with accessibility to ARV services and should be addressed during scaling up 
of ART programmes.  
 
Exploring these different variables shows that they are interrelated in complex ways in 
their impact on adherence whereby the health care system provides an interface between 
most of the factors that affect adherence. For instance, health care systems determine the 
medication distribution systems and continuity of care which directly or indirectly affect 
adherence. Similarly, health care systems allocate human and drug resources 
consequently affecting accessibility, quality of counselling, intervals between 
appointments, all which impact on patients’ adherence behaviour.  
 
Whilst all these factors highlight the key role of the health care system in supporting 
adherence, it is widely recognized that, targeting the health system alone is not sufficient. 
Hence adherence promoting interventions should address the full range of contextual 
factors that affect adherence in order to enhance adherence to HAART. This argument is 
echoed by the WHO Report which acknowledged the complexity of the factors that affect 
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adherence and recommended a multifaceted approach to improve adherence (WHO, 
2003a).  
 
2.5. SUMMARY  
Adherence has been identified as a key element in reducing the likelihood of the 
emergence of drug resistant virus. Hence, the recent global efforts towards increasing 
access to ARV in resource limited settings, should match availability of ARV with 
successful treatment outcomes to avoid the emergence of drug resistant strains. Though 
earlier apprehension of low levels of HAART adherence in resource limited settings has 
been proven unfounded, adherence may still be a concern in the region. Identifying 
contextual factors that affect adherence to HAART is an important process in designing 
interventions aimed at sustaining optimal adherence levels.  
 
The next chapter outlines the specific objectives of the present study and the 
methodology used to achieve these objectives. 
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CHAPTER 3  
3. AIM AND OBJECTIVES 
3.1. AIM OF THE STUDY  
The aim of this study was to obtain baseline data on adherence levels and to identify the 
major determinants of adherence among adult patients on HAART at Rundu Hospital, 
Namibia. 
 
3.2. OBJECTIVES OF THE STUDY  
1. To measure the adherence rates among adult patients on first line HAART regimens at 
Rundu Hospital 
2. To measure barriers to optimal adherence among adult patients on first line HAART 
regimens at Rundu Hospital. 
3. To measure factors that facilitate optimal adherence among adult patients on first line 
HAART regimens at Rundu Hospital. 
4. To analyse the association between the identified factors and adherence among adult 
patients on first line HAART regimens at Rundu Hospital. 
 
3.3. SIGNIFICANCE OF STUDY  
This study is the first of its kind in Namibia and hence the findings may be useful in 
developing appropriate intervention strategies to improve and sustain optimal adherence 
in patients on HAART in similar settings in Namibia. This is particularly important given 
the ongoing countrywide roll-out of the ART programme in Namibia. In addition, the 
study may provide baseline adherence data that could facilitate the comparison of the 
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ART programme in Namibia with other similar programmes in the sub - Saharan Africa 
region. 
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CHAPTER 4 
4. METHODOLOGY  
4.1. STUDY DESIGN 
A cross-sectional survey with both descriptive and analytical components was 
undertaken. The descriptive component aimed to describe the socio-demographic 
characteristics, adherence rates and magnitude of barriers and facilitators of adherence 
among adult patients on HAART in Rundu Hospital whilst the analytic part aimed to 
identify the barriers and facilitators of adherence. 
The design was selected to enable measurements of adherence and exploration of 
associated factors at the same time for a baseline measure. 
 
4.2. STUDY SETTING  
Rundu is a peri-urban district in the Kavango Region located in the North East of 
Namibia. The catchment population is 117,000 and the major source of income is 
subsistence farming. Rundu Hospital is a 200 bed hospital which functions both as a 
district hospital and a referral hospital for three other district hospitals: two in the 
Kavango region and one in the Caprivi region.  
 
Rundu Hospital commenced its ART programme in 2003 and by June 2007, 1300 adult 
patients were receiving HAART at the hospital, with an average monthly uptake of 50 
patients (MOHSS, 2007). Approximately 95% of these HAART patients were on first 
line regimens which comprised two nucleoside reverse transcriptase inhibitors (NRTI) 
and a non nucleoside reverse transcriptase inhibitor (NNRTI). Patients on second line 
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regimes receive two nucleoside reverse transcriptase inhibitors (NRTI) and a protease 
inhibitor (PI) in place of the nucleoside reverse transcriptase inhibitors (NRTI) (MOHSS 
2003). The NRTIs currently used for first line are Lamivudine, Stavudine, Zidovudine 
and Tenofovir. NNRTIs used are Nevirapine and Efavirenz while the PI used is boosted 
Lopinavir. The NRTIs are available as fixed combined doses as Lamivudine and 
Stavudine or Lamuvudine and Zidovudine so as to simplify regimens. 
 
Patients on HAART receive treatment free of charge at the hospital. Adult patients for 
follow up appointments are seen at the Chronic Disease Clinic (CDC) daily and the 
names of patients due for follow up on a particular day are obtained from the computer at 
the clinic. On arrival, patients are received at the reception area where their files are 
retrieved by the data clerk and then seen by the nurse. The nurse checks the vital 
parameters like temperature, blood pressure and weight and then directs the patients to 
the doctor who prescribes the drugs and determines the next follow-up appointment dates 
which are usually after two months. Thereafter the patients go to the pharmacy where 
their remaining pills are counted and new ones dispensed. The total number of pills that 
the patient takes home is either recorded in the patients’ health cards or on the pill 
container labels. Since the patients take their health cards home, the records at the 
hospital only reflect the number of pills that are dispensed to the patient and not the total 
number that the patient takes home.  
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4.3. STUDY POPULATION 
The study population was patients aged 18 years and above who were on first line 
regimen of HAART and attending Rundu Hospital at the time of the study. Inclusion 
criteria were:  
? Patients aged 18 and above 
? Patients on first line regimens of HAART 
? Patients who had been receiving HAART at Rundu Hospital for at least 6 months 
prior to the commencement of the  study  
? Patients who  gave  informed consent to participate in the study 
? Patients who attended  follow up appointments during the study period 
 
The study population was estimated to be 1,300 based on CDC data (MOHSS, 
2007a). 
The rationale for selecting the study population was that adherence measures in 
patients under 18 years of age, may on average, be more likely to be influenced by 
factors related to supervision of medication by caregivers’ rather than particular 
choices made by the patients themselves. Patients on first line regimen were chosen, 
because second line treatment was reserved for patients who had failed on first line 
treatment and this may have confounded the study. The choice of the duration on 
treatment was based on the assumption that patients on treatment for six months or 
less were given one month of follow up while the rest were given follow up 
appointments of two months. 
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4.4. SAMPLING 
 The sample size was determined using survey Epi Info version 3.3 (CDC, 2004) for 
calculation of sample size for a population survey. The study population was estimated to 
be 1,300 based on CDC data (MOHSS, 2007a) and the expected prevalence of patients 
achieving optimal adherence (taking > 95% of medication) was between 84% as the best 
acceptable rate and worst acceptable estimate was 75% (Personal communication with 
Mano: 12 September 2007). The estimates were based on two provider estimates using 
pill count records at the pharmacy. Using 95% confidence levels, the required sample 
size was 61 patients. In this study, it was decided to include 100 participants to account 
for those who might decline to participate. A list of names of patients due to attend 
scheduled follow up to CDC for the period between 4th December 2007 to 7th Dec 2007 
was obtained from the clinic. From this list, patients who did not meet the inclusion 
criteria were excluded to form a sampling frame of 347 patients. From this sampling 
frame, every third patient was selected resulting in a sample of 115 patients. This was 
done to cover for patients who might not turn up since the list was drawn beforehand and 
some selected patients might miss their appointments.  
 
4.5. DATA COLLECTION TOOL  
The data collection tool used was a structured adherence questionnaire in English.  The 
questionnaire was adapted from the adherence measurement tools used in similar studies 
in Botswana and Tanzania to suit the Namibian setting (Kgatlwane et al, 2006: Irunde et 
al, 2006).  The adherence measurement methods used were 2 day recall using a sun and 
moon chart, 30 day recall using a visual analogue scale and pill count. The administration 
 
 
 
 
31 
 
of the questionnaire was preceded by providing participants with an information sheet 
and an informed consent form; both of which were in English and Rukwangali, the local 
language, in order to facilitate understanding of the contents. 
 
The questionnaire which was composed of seventeen questions was divided into three 
parts (appendix 5). The first part collected socio- demographic data, the second part 
collected data related to treatment and the third part comprised the adherence 
measurement tools. 
 
4.5.1. SOCIO-DEMOGRAPHIC DATA. 
The socio-demographic data included age, sex, and marital status, level of schooling and 
place of residence. Age was obtained using month and year and then computed later. 
Similarly, distance to hospital was computed from data obtained on the place of residence 
of the participant and the nearest health facility. Collecting data in this manner ensured its 
accuracy and facilitated verification of socio-demographic data the data from the 
patients’ health cards.  
 
4.5.2. TREATMENT DATA 
The data collected on treatment included duration on treatment, experience with side 
effects and knowledge of consequences of failing to take medication as prescribed. Like 
age, duration on treatment was collected as month and year while all the other questions 
were in a multiple choice format. The questions on reasons for missing doses and 
appointments were phrased in a nonjudgmental manner. The question on treatment 
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regimens required verification of the patients’ pill containers with the patients’ health 
cards to ensure accuracy. 
 
4.5.3. ADHERENCE MEASUREMENT TOOLS 
The third part of the questionnaire collected adherence data using three different 
measures: a 30 day self report using a visual analogue scale, 2 day recall using a sun and 
moon chart and a pill count.  The 30 day visual analogue scale required participants to 
pour beads from one container representing the pills they were supposed to have taken in 
a period of 30 days, into another container representing the pills actually taken in the 
same period. The pills left in the first container therefore represented the pills missed and 
adherence was then measured using a line marked 1-10 on the first container. This was 
done for each drug in the regimen. The use of beads in the visual analogue scale instead 
of a single line provided a more demonstrative and relevant measure to participants 
especially those with low education levels. 
 
The 2 -day recall used a sun and moon chart that also indicated time in one hour intervals. 
The participants were required to state the time when the dose of each drug in the 
regimen was taken starting from the previous day to two days prior. Adherence was then 
calculated as a percentage of the interval between the doses in relation to the interval 
required. The use of a sun and moon chart was selected as it illustrated time in a concept 
that was relevant to patients in this study setting. 
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The pill count was obtained by determining the number of pills returned, the number of 
pills dispensed in the previous refill and the number supposed to have been taken in a 
given period. This information was obtained from the pill containers and the patients’ 
cards. Adherence was then calculated as the number of pills supposed to have been taken 
minus the number of pills missed in a given period as the numerator and the total number 
of pills supposed to have been taken in the same period as the denominator. This was 
calculated for each drug in the regimen and the average computed. Adherence rates that 
were over 100% using this adherence measure were recorded as 100%. 
 
4.6. PILOT STUDY  
A pilot test was conducted on patients receiving HAART at the CDC in Rundu Hospital 
in November 2007. Prior to data collection, the hospital pharmacist and the medical 
superintendent of Rundu Hospital were informed about the study and were provided with 
copies of the information sheet, consent form and questionnaire. The research team 
comprised of the chief researcher and four research assistants. The chief researcher was 
the author while the research assistants were one trainee pharmacist and three trainee 
nurses. The exercise was used to test the data collection tool for clarity, cultural 
sensitivity and the suitability of the questions to capture the relevant data. The pilot study 
also acted as a practical training session for the research assistants and in particular to 
introduce them to the concepts of adherence measures that would be used in the study. 
The pilot study was also used to test the applicability of the standard procedure code for 
the questionnaire. 
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Thirty patients, who were representative of the proposed sample for the main study, were 
selected from a list of those attending the clinic on three days using a systemic sampling 
method.  The pilot study resulted in changes in the study inclusion criteria and also to the 
questionnaire. In respect to the inclusion criteria, it was discovered that patients who had 
been on treatment for six months and less were given a one month follow up while 
patients on longer treatment duration were given a follow up appointment of two months. 
Consequently, the inclusion criterion was changed from patients being on HAART for at 
least three months to being on HAART for at least six months. 
 
In the case of the questionnaire, it was found that due to lack of reliable transport, many 
modes of transport including bicycles and donkey carts were used. Thus, the cost of 
travelling to Rundu hospital varied even for patients from the same place resulting in the 
question on travel costs not being a very sensitive indicator of transport costs. In addition, 
participants found it difficult to estimate the distances from home to the hospital and the 
question was changed to collect the place of residence and the nearest health facility. The 
distance from the health facility to the hospital was then used to calculate a proxy 
measure of the distance from home to the hospital. This strategy was utilized because 
some inland areas were not reflected in the local maps which would be used to compute 
the distance. The questions on missed doses and appointments were found to require 
more probing in order to elicit effective response and this instruction was included in the 
data collection procedures for the research assistants.  
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It was observed that patients tended to respond that they had not missed any doses when 
the chief researcher administered the questionnaire or was present during the interview 
but were more open with the research assistants. A possible reason was that there were 
issues of social desirability because unlike the rest of the research team, the chief 
researcher was a former pharmacist at Rundu Hospital and was known to most of the 
patients. Subsequently, it was decided that the chief researcher would not participate in 
the interviews. In addition the current hospital pharmacist gave input on the data 
collection process relative to the patient flow and as a result it was decided that the pill 
count should be conducted at the waiting room as the space in the pharmacy was not 
adequate. Finally, by piloting, it was discovered that HAART patients were seen at CDC 
four days a week (Tuesdays to Friday) and not two as earlier stated. Consequently data 
collection was done in four days in one week and not over two weeks as originally 
planned. 
 
4.7. DATA COLLECTION PROCEDURE  
Four research assistants conducted the interviews with patients on HAART at Rundu 
hospital between the 4th and 7th December 2007.  The research assistants, who were 
divided into two teams, both stationed in the waiting area where the patients waited prior 
to seeing the doctor.  
The first team of research assistants used the list to identify the selected patients using 
ARV numbers and thereby proceeded to introduce themselves, the information sheet and 
consent form to the participants. Only after the participants had signed the consent form, 
did the interviews commence with questions from the first and second parts of the 
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questionnaire covering socio-demographic and treatment related issues. The completed 
questionnaire was then coded using the patients’ ARV number before being passed on to 
the second research team. 
 
This second team first checked the questionnaire for completeness of information 
collected by the first team and then confirmed that the ARV number on the questionnaire 
corresponded to the ARV number on the patients’ health card and that on the patient’s 
pill containers. Next, the research assistants filled in details of the patient’s treatment 
regimen on the questionnaire by confirming that the pills prescribed on the patients’ 
passport were the same as the pills or containers presented by the patient. The research 
assistants then proceeded with the 30 day and 2 day adherence self report using the pill 
containers to ensure that adherence was reported for each drug in the regimen. This 
second team also obtained pill count data from the patients’ cards, pill containers and 
actual counting of the returned pills. Finally the questionnaire was checked for 
completeness by the chief researcher before the patient left the CDC clinic. Double 
checking was carried out in order to ensure accuracy and completeness, while at the same 
time maintaining a smooth flow of participants.  
 
 
4.8. DATA MANAGEMENT AND ANALYSIS  
All answers to questions requiring computing were entered on the questionnaire in a 
distinct color and then double checked by the chief researcher for completeness and 
accuracy at the end of each day. A written code book detailing standard procedures, 
 
 
 
 
37 
 
which was developed by the chief researcher after the pilot study, was used to code the 
questionnaires which were then double entered into Excel files by two different research 
assistants. The two files were then compared and any anomalies or missing data between 
the two entries were checked using the questionnaires. The entered data was then 
scrutinized for invalid values and impermissible combinations and counterchecked with 
the questionnaires. This data was then exported into Epi Info version 3.3 (CDC, 2004). 
 
Means, medians, standard deviation, range and frequency distributions were computed 
for all continuous variables. The three measures of adherence were evenly weighted to 
obtain a composite adherence. Two measures of adherence were computed: one measure 
established the overall patient adherence rate while the second measure determined the 
proportion of patients in each of   the two or three adherence categories.  
 
Adherence was analysed both as a categorical variable expressed as high (> 95%), 
moderate (85%-94%) and low adherence (< 85%) level; and also as a dichotomous 
variable as optimal (> 95%) and sub optimal levels (95%). Categorizing adherence into 
high, medium and low levels during statistical analysis facilitated the exploring of 
patients’ adherence behaviour which is relevant in intervention studies (Bangsberg, Moss 
& Deeks, 2004). On the other hand, categorizing adherence into optimal and suboptimal 
adherence defines a clinically relevant cut off that has been shown to be linked with 
treatment outcomes (Patterson et al, 2000). Since the main objective of this study was to 
provide baseline data, adherence was categorized as dichotomous and also in the three 
levels for analysis.  
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Bivariate analysis was done to test the association between outcome variables (2-day 
recall: 30 day recall: pill count and composite measure) and predictor variables (age: sex: 
marital status: education level: disclosed status: regimens: ART knowledge: and reported 
side effects) separately. The Chi-squared test with a 95% confidence level was used 
except in cases where the expected cell size counts were less than 5 when the Fischer 
exact test was used instead. The Prevalence Ratio and 95% confidence interval were used 
as the measure of effect, in preference to Odds Ratio. The justification for this being that 
this was a cross-sectional study and as such, lacked longitudinal data, hence Prevalence 
Ratio was a more relevant measure than the Odds Ratio which would have tended to 
underestimate or overestimate the effect (Thompson, Myers & Kriebel, 1998).   
 
4.9. VALIDITY AND RELIABILITY  
The issues of validity and reliability in the study were addressed in a number of ways. 
Selection bias was addressed by using the list of patients expected to attend the CDC 
clinic at the hospital on the data collection days as the sampling frame, and using a 
systematic sampling process. Chance was further reduced by increasing the sample size. 
Measurement bias was reduced by the use of multiple adherence measures to ensure 
accuracy of adherence estimates, as strengths of one method compensate for the 
weaknesses of the other (Liu et al 2001: Arnsten, et al, 2001).  Moreover, the use of the 
different measures facilitated the measurement of different dimensions of adherence thus 
addressing content validity.   
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The piloting, training of research assistants and the coding procedures ensured a 
standardised questionnaire which further minimized measurement bias. The data 
collection tool was adapted from a questionnaire that used in other studies in similar 
settings (Kgatlwane et al, 2006: Irunde et al 2006). The visual analogue scale and 2 day 
recall methods were found to be valid instruments for measuring adherence in Uganda 
(Oyugi et al, 2004). Similarly, four day recall, visual analogue and pill count as methods 
for estimating adherence were also validated using MEMS in a study in a clinical setting 
in South Africa (Steel, Nwokike & Joshi, 2007). Moreover, the use of measurement tools 
like the beads for visual analogue scale and sun and moon chart ensured that the 
measures were relevant to the study population which further increased the sensitivity of 
the collection tool. Social desirability usually associated with self reporting was 
minimized by phrasing the adherence questions in a non threatening manner; and by the 
use of research assistants to administer the questionnaire to the participants, rather than 
the chief researcher, who as a former pharmacist at the hospital was known to the 
participants. 
    
4.10. GENERALISABILITY 
The sampling method ensured that the participants were representative of the study 
population attending CDC clinic at Rundu Hospital in one week of the year. As there is 
no reason to believe that this population is any different from the total population of adult 
patients on the first line HAART regimens at Rundu Hospital, the results of this study 
may be generalisable to the study population.  
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4.11. LIMITATIONS 
This study had a number of limitations. Firstly, with respect to sampling, the systematic 
sample of adult HAART patients was drawn from patients attending the CDC clinic in 
one week period rather than from the whole population on HAART. This was due to 
practicalities in data collection however there was no reason to believe that the week 
chosen was any different from the other weeks in the year. 
 
Secondly, the study population included patients still on treatment at the time of the study 
and so patients who had discontinued therapy for any reason were excluded from the 
study which may have meant that poor adherers were missed. Additionally, patients who 
missed their appointment would also not have been included in the study. Both these 
factors may result in overestimating adherence levels.  
 
Finally, there were limitations due to the adherence measures used in this study. The use 
of self report could have overestimated adherence although a number of recent studies 
have shown the reliability of self report as an adherence measure (Simoni et al, 2006: 
Nwokike, Steel & Joshi, 2006). The announced nature of the pill counts could have 
resulted in pill dumping which would have resulted in overestimation of adherence. 
However, the use of composite adherence measures could have mitigated the 
overestimation of adherence effects of these measures. Validating the adherence levels 
obtained with viral loads is ideal in adherence studies, however, at the time of the study, 
viral load testing was not done at Rundu Hospital and any patients requiring viral loads 
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were referred to Windhoek. Thus the unavailability of viral loads in this study as in 
similar studies in resource poor settings is a limitation.  
 
4.12. ETHICAL CONSIDERATIONS  
Prior to the study, ethical approval was obtained from the University of Western Cape 
and the Ministry of Health and Social Services, Namibia. In addition, permission was 
obtained from the Medical Superintendent of Rundu Hospital.  
 
Participants were informed of the purpose of the study and the procedures to be taken to 
ensure confidentiality of personal information. Similarly, participants were informed that 
participation in the study was voluntary and that they could terminate their participation 
at any time without giving reasons and with no recriminations against them. They were 
also informed that there were no benefits or risks associated with this study and were   
encouraged to seek clarification on any aspects of the study. The information sheet and 
the consent form were available in both English and Rukwangali and were read to those 
who were unable to read.  
 
Only after participants had understood this information were they invited to sign the 
consent form which was then obtained from each participant before commencing the 
interview. The information obtained was password protected and was only available to 
the chief researcher.   
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CHAPTER 5 
RESULTS   
5.1. DESCRIPTIVE PARTICIPANT CHARACTERISTICS  
5.1.1. PARTICIPANT SOCIO-DEMOGRAPHIC CHARACTERISTICS  
Ninety- seven participants were included in the study, a response rate of 84.3%. Out of a 
total of one hundred and fifteen participants that met the eligibility criteria, eleven did not 
turn up for their follow up appointment during the study period, five declined to 
participate in the study and two did not personally collect their treatment as they had been 
admitted at the hospital. Of the ninety seven ARV patients that participated in the study, 
78 % (76) were female, the mean age was 36.7 (SD: 9.00) years and 80% (77) of the 
participants were in the 20-44 age group. Approximately half (49/97) of the participants 
were married or cohabiting and just less than half (48/97) had secondary school education 
and above while 14% (14) reported having received no formal schooling at all. Table 1 
summarises the socio-demographic characteristics of the participants.  
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Table 1: Participant Characteristics (n=97) 
VARIABLE  No (%) 
GENDER   Male 21  (22) 
  Female 76  (78) 
AGE  (Years)  20-24 8    (8) 
  25-29 16  (17) 
  30-34 21  (22) 
  35-39 13  (13) 
  40-44 19  (20) 
  45-49 13   (13)
  50-54 4     (4) 
  55-59 1    (1) 
  60+ 2    (2) 
MARITAL STATUS  Married /cohabiting 49  (51) 
  Divorced 11   (11)
  Single 13   (13)
  Widowed 24   (25)
EDUCATION LEVEL  None /incomplete primary 17   (18)
  Primary 32   (33)
  Secondary 46   (47)
  Tertiary 2(2) 
 
 
5.1.2. DISTANCE TO HOSPITAL 
Most participants (63%; 61/97) travelled between three and ten kms from their home to 
the hospital, while 13% (13) reported that they had to travel over 50 kms. The median 
distance was 6.0 (IQR: 5-19) kms while the maximum distance travelled by one 
participant was 163kms. Table 2 shows the distances travelled by the participants to the 
hospital. 
 
 
 
 
 
 
 
44 
 
Table 2: Distances travelled by participants to the hospital (n=97) 
DISTANCE (km) No. (%) 95% CL 
< 10 61 (63) 52.5 - 72.5
11-20  16 (17) 9.7 - 25.4 
21-30 4 (4) 1.1 - 10.2 
31-40 2 (2) 0.3 - 7.3 
41-50 1 (1) 0.0 - 5.6 
> 50  13 (13) 7.3 - 21.8 
 
 
5.1.3. ART TREATMENT REGIMENS  
Most of the participants (83%: 80/97) were on treatment combinations that contained 
nevirapine and a combination of either stavudine and lamivudine or zidovudine and 
lamivudine which had the same daily dosing of twice daily. The remainder were on 
treatment combinations that contained efavirenz which requires a once daily dose and as 
a result, these drug combinations had components that required different daily doses 
which complicated the dosage. Table 3 shows the patients ART regimens and their daily 
dosing. 
 
Table 3: Participants ART regimens (n = 97) 
ART REGIMEN S Daily dosing No. (%) 
Stavudine + Lamivudine (combined Pill)  & Nevirapine  bd & bd 59(61%) 
Zidovudine + Lamivudine (combined Pill)  & Nevirapine bd & bd 21(22%) 
Stavudine + Lamivudine  (combined Pill) &  Efavirenz   bd & od 9(9%) 
Zidovudine + Lamivudine (combined Pill) & Efavirenz  bd & od 1(1%) 
Tenofovir & Lamivudine & Efavirenz  od & bd & od 7(7%) 
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5.1.4. DURATION ON ART TREATMENT 
Figure 1 shows the length of time participants had been on ART treatment. The mean 
duration that participants had been on ART treatment was 20 (SD: 10.3) months while 
the median was 17 (IQR: 17 – 24) months. Approximately 76% (73) of the participants 
had been on ART for 24 or less months.  
     
       Figure 1: Duration on ART treatment (n =97) 
 
 
5.1.5. SIDE EFFECTS REPORTED AND DISCLOSURE OF STATUS 
About a third (32/97) of the participants reported having experienced some side effects 
with ART medication.  In addition, 83% (81) reported having disclosed their HIV status 
to somebody else apart from the mandatory treatment supporter. 
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 5.1.6. ART KNOWLEDGE  
When asked the consequences of failing to take ART medication as prescribed, 45% (n = 
44) of the participants answered that their health would deteriorate while 24% (n= 23) of 
the participants answered that the viral load would increase. A further 4% (n = 4) 
answered that the virus would become drug resistant. Approximately 27 % (n = 26) of the 
participants   answered that they did not know. Any of the first three answers was 
considered as ART knowledge while a “don’t know answer” was considered no ART 
knowledge. 
 
5.1.7. RATES OF ADHERENCE  
The mean adherence rates obtained using 30 day self report (visual analogue), 2 day self 
recall (sun and moon chart) and pill count were 91%, 99% and 94% respectively. The 
mean composite adherence of the three measures gave an adherence rate of 95%. The 
mean adherence rates are shown in Table 4. 
 
Table 4:  Mean Adherence rates  
ADHERENCE MEASURE % MEAN ADHERENCE (SD) 
30 day SR visual analogue ( n = 97) 91.3  (11.23) 
2 day SR sun & moon chart  (n= 93) 99.4  (2.26) 
Pill count  ( n= 95) 94.8  (7.51) 
Composite adherence of the 3 measures (n = 97) 95.1  (4.94) 
 
The proportion of ARV patients who achieved optimal adherence levels (95% and above) 
was 55%, 94% and 74%  using 30 day visual analogue, 2 day recall and pill count 
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respectively. Using the mean composite of the three adherence measures, it was found 
that 64% of the ARV users had achieved optimal adherence levels. The adherence level 
categories of the ARV users obtained by each adherence measure are shown in Table 5. 
 
Table 5: Proportion of ARV participants per adherence category  
  CATEGORY OF ADHERENCE  
ADHERENCE MEASURE  High ( 95-100) Moderate (85-< 95) Low ( < 85) 
30 day SR visual analogue  
 n=97 
53(55%) 
 (95% CI: 44.2-64.8%)
24 (25%) 
( 95% CI :16.5-34.5%) 
20 (20%)  
(95% CI: 13.1-30.0 %)
2 day SR sun & moon chart n=93 87 (94%) 
(95% CI: 86.5-97.6%) 
6 (6%)  
(95% CI: 2.4- 13.5%)  
 
0% 
Pharmacy Pill count  n=95 70(74%) 
95% CI: 63.6-82.2 %) 
16(17%)  
(95% CI: 9.9-25.9 %) 
9(9%)  
(95%CI: 4.4-17.2%) 
Composite adherence of  
the 3 measures n=97 
62 (64%) 
(95% CI: 53.5-73.4 %)
31 (32%)  
 (95% CI: 22.9-42.2%) 
4 (4%)  
(95% CI: 1.1-10.2%) 
    
 
 
5.1.8. REASONS GIVEN FOR MISSING DOSES  
Half of the participants (49/97) reported that they had not missed any doses and thus 
could not give reasons. The most common reasons given by the participants for 
missing doses were forgetfulness (28%), lack of food (13%) and not having the pills 
with them (11%). Participants were allowed to give a maximum of three reasons. 
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 Table 6: Reasons given for missing doses (n = 48) 
REASONS NO. CITED REASON % 
Forgot 27 28
Lack of food 13 13
Being away from pills 11 11
Alcohol use 1 1 
Reacted to medication 1 1 
Instructions not understood 1 1 
 
 
 
5.1.9.   FACILITATORS FOR TAKING DOSES CORRECTLY 
 Fifty eight percent (n = 56) of the participants reported using reminders like cell 
phones and radio to remember to take their medication on time. In addition, 19% 
reported that having treatment supporters was a facilitator, while a further 11% cited 
counselling as the main factor that facilitates them in taking   their medicines 
correctly. 
 
     5.1. 10.   REASONS GIVEN FOR MISSING ARV CLINIC APPOINTMENTS  
Similar to missing doses, 61% (n = 59) of the participants reported that they had not 
missed any appointments. The most common reasons mentioned for missing refill 
appointments were lack of transport money (22%) and forgetfulness (6%). Other 
reasons given were feeling ill (3%) and not being able to have time off from work 
(2%). 
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5.2   FACTORS AFFECTING ADHERENCE TO ANTIRETROVIRALS 
Associations were tested between adherence and categorical variables. In the analysis, 
2X2 tables were set up to test the associations between outcome variables (2-day 
recall; 30-day recall; pill count; and composite measure) and predictor variables (sex; 
marital status; educational level; disclosed status; ART regimens; ART knowledge; 
and reported side effects) separately. Association was tested using high, medium and 
low adherence and also using the dichotomous categories of optimal and suboptimal 
levels of adherence in the sensitivity analysis. For the 2 day recall, only the 
dichotomous categories were used as there were no participants in the low adherence 
category. Association was tested using 95% significance level (p < 0.05), and using 
the Fischer exact test when expected cell size counts were less than 5.  
 
Having ART knowledge was found to be significantly associated with being highly 
adherent (p value=0.03) while being male was found to be significantly associated 
with being optimally adherent (p=0.04). Marital status and education level were not 
found to be significantly associated with adherence. Other categorical predictor 
factors that were found not to be significantly associated with adherence were ART 
regimens, disclosed HIV status and reported side effects. (See tables 1 to 12 in 
appendix 6). 
 
In addition, association between the different measures of adherence was tested by 
dichotomising the numerical variables (distance, age and duration on treatment) using 
either the median or the mean as the cut off point. These analyses were done with 
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adherence as a dichotomous variable as the values of low adherence (< 85%) were 
almost nil for the three numerical variables. Association was tested using Chi-squared 
test with 95% confidence level, and using the Fischer exact test when expected cell 
size value was than 5.  
Living within a distance of 6km from the hospital was significantly associated with 
being optimally adherent (p = 0.018) while participant’s age and duration on ART 
were no found to be significantly associated with adherence. (See tables 13 to 15 in 
appendix 6).  
 
 
 
5.2.1   ART KNOWLEDGE 
Having knowledge of consequences of failing to take medication as prescribed was 
found to be significantly associated (p=0.03) with being highly adherent >95 when 
using composite adherence with the 3 categories of adherence. This association, 
however, was not observed when composite adherence was in dichotomous 
categories. Similarly, no significant association was observed with the other measures 
of adherence. Tables 7 and 8 show the bivariate analysis of ART knowledge using - 
adherence in the three categories and dichotomous categories respectively.  
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Table 7: Bivariate analysis of ART knowledge using adherence in three 
categories  
  Adherence   Category   
Adherence Measure ART Low Medium High χ² p 
 Knowledge < 85% 85 - < 95 % 
>95%  value 
30 day recall adherence  n  
= 97 
 
 
 n (%) 
20 (20) 
n (%) 
24 (25) 
n  (%) 
53 
(55) 
  
Yes 14 (20) 20 (28) 37 
(52) 
1.67* 0.43 
No 6 (23) 4 (15) 16 
(61) 
  
Pill count n = 95 
 
 
 n (%) 
9 ((9) 
n (%) 
16 (17) 
n  (%) 
70 
(74) 
  
Yes 6 (9) 15 (21) 49 
(70) 
4.04* 0.13 
No 3(12) 1 (4) 21 
(84) 
  
Composite adherence   n=  
97 
 
 
 n (%) 
4 (4) 
n (%) 
31(32) 
n  (%) 
62 
(64) 
  
Yes 1 (1) 26  (37) 44 
(62) 
6.69 
* 
0.03 
No 3 (12) 5 (19) 18 
(69) 
  
* Fischer Exact Test used 
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Table 8: Bivariate analysis of ART knowledge using adherence in dichotomous 
categories  
  Adherence Category    
Adherence measure 
ART Sub 
optimal 
Optimal Prevalence χ² P 
Knowledge <95 % >95% Ratio (95% 
CI) 
 value 
30 day recall 
adherence 
n = 97 
 n (%) 
44 (45) 
n (%) 
53(55) 
   
Yes 34 (48) 37 (52) 1.11 (0.87 - 
1.44) 
0.35 0.55 
No 10 (39) 16 (61)    
2 day recall 
adherence 
n = 93 
 n (%) 
6 (6) 
n (%) 
87(94) 
   
Yes 4 (6) 64 (94) 0.74 (0.14 -
3.77) 
0.14* 0.65 
No 2 (8) 23 (92)    
Pill count 
n = 95 
 n (%) 
25 (26) 
n (%) 
70 (73) 
   
Yes 21 (30) 49 (70) 1.20 (0.95 - 
1.51) 
1.21* 0.27 
No 4 (16) 21 (84)    
Composite 
adherence 
n = 97 
 n (%) 
35(36) 
n  (%) 
62 (64) 
   
Yes 27 (39) 44 (61) 1.09 (0.85 - 
1.38) 
0.43 0.50 
No 8 (31) 18 (69)    
*Fischer exact test used 
 
5.2.2   GENDER  
Being male was found to be significantly associated (p = 0.04) with being optimally 
adherent when using the 30 day visual analogue in the dichotomous categories.   No 
significant association was observed with the other adherence measures when tested 
either in the three or dichotomous categories.  Tables 9 and 10 show the bivariate analysis 
of gender using adherence in the three and dichotomous categories respectively. 
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Table 9: Bivariate analysis of Gender using adherence in the three categories  
 
 
 
 Adherence    Category   
Adherence measure Gender
 
Low Medium High χ² P 
 < 85% 85 - <95 % >95%  Value 
30 day recall adherence 
 n = 97 
 
 
 n (%) 
20 (21)
n (%) 
24 (25) 
n (%)  
53(54) 
  
Female 17(22) 22(29) 37(49) 5.31* 0.07 
Male 3(14) 2(10) 16(76)   
Pill count n = 95 
 
 
 n(%) 
9 (9) 
n(%) 
16(17) 
n(%) 
70(74) 
  
Female 9(12) 13(18) 52(70) 3.19* 0.2 
Male 0 3 9(14) 18 (86)   
Composite adherence  
n = 97 
 
 
 n(%) 
4 (4) 
n(%) 
31(32) 
n(%) 
44(45) 
  
Female 4 (5) 27(36) 45(51) 2.41* 0.12 
Male 0 4 17   
*Fischer Exact test used  
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Table 10: Bivariate analysis of Gender using adherence in dichotomous 
categories  
  Adherence Category    
Adherence measure 
Gender Sub-
optimal 
<95 % 
Optimal 
>95% 
Prevalence 
Ratio (95% 
CI) 
χ² P 
 value 
30 day recall 
adherence 
n=97 
 
 
 n (%) 
44 (45) 
n (%) 
53 (55) 
   
Female 39 (51) 37 (49) 1.27  
(1.03 - 1.56) 
3.97 0.04 
Male 5 (24) 16 (76)    
2 day recall adherence 
n= 93 
 
 
 n (%) 
6 (6) 
n (%) 
87 (94) 
   
Female 5 (7) 68 (93) 1.07 
 ( 0.73 - 1.55) 
0.05* 1.00 
Male 1(5) 19(95)    
Pill count 
n = 95 
 
 
 n (%) 
25 (26) 
n (%) 
70 (74) 
   
Female 22 (30) 52 (70) 1.18  
(0.97 - 1.45) 
1.29* 0.25 
Male 3 (14) 18 (86)    
Composite adherence 
n = 97 
 
 
 n (%) 
35 (36) 
n (%) 
62 (64) 
   
Female 31 (41) 45 (59) 1.22  
(1.01 -1.48) 
3.37* 0.06 
Male 4 (19) 17 (81)    
*Fischer exact test used 
 
 
5.2.3. MARITAL STATUS / EDUCATION LEVEL  
No significant association was found between marital status and adherence using any of 
the three adherence measures or composite adherence as high, medium and low 
categories ( p-values: 0.82:  0.54: 0.12 for 30 day recall,  pill count and composite 
adherence respectively). This lack of significant  association was  also observed when 
adherence  as dichotomous categories of optimal and sub optimal adherence ( p-values 
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0.67: 0.91: 0.45: 0.31 for 2day recall, 30 day recall, pill count and composite adherence 
respectively). 
Similarly, no significant association was found between education level and any of the 
adherence measures when analysed as high, medium and low categories resulting in p-
values of ,  0.33: 0.23: 0.76 for 30 day recall,  pill count and composite adherence 
respectively.  Likewise, no significant association was observed between education level 
and adherence in dichotomous categories of optimal and sub optimal adherence with p-
values of 1.00: 0.48: 0.14: 0.47 for 2day recall, 30 day recall, pill count and composite 
adherence respectively. The complete analysis data is presented on Tables 6 and 7 in 
appendix 6. 
 
5. 2.4.  ART TREATMENT REGIMENS/DISCLOSED STATUS  
No significant association was found between ART treatment regimens of using any of 
the three adherence measures or composite adherence when analyzed as high, medium 
and low categories giving p-values of 0.25: 0.87: 0.11 for 30 day recall, pill count and 
composite adherence respectively. Similarly, no significant association was observed  
when adherence was analyzed  as dichotomous categories of optimal and  sub optimal 
adherence ( p-values,0.24: 0.50: 1.00: 0.52 for 2day recall, 30 day recall, pill count and 
composite adherence respectively).  
 
This lack of significant association was also observed with disclosure of HIV status and 
adherence. When adherence was analyzed as optimal and sub optimal categories, p-
values were 0.65: 1.00: 0.33: 0.75 with 2 day recall, 30 day recall, pill count and 
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composite adherence respectively. Correspondingly, when adherence was analyzed as 
three categories of low, medium and high, resulting p-values were 0.45, 0.36 and 0.64 for 
2 day recall, 30 day recall and composite adherence.  The complete data is also presented 
on Tables 6 and 7 in appendix 6. 
 
5.2.5.   DISTANCE TO HOSPITAL  
Distance to the hospital was dichotomised using the median (6 km) as the cut off point. 
Living within a distance of 6km from the hospital was significantly associated with being 
optimally adherent when using composite adherence (p=0.018) as the adherence measure. 
No significant association was observed when using adherence with the other adherence 
measures. Table 11 shows the bivariate analysis of adherence with median distance as the 
cut off. 
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Table 11: Bivariate analysis of adherence with median distance as the cut off  
  Median distance   = 6 km    
  Adherence Category    
Adherence 
measure 
distance Suboptimal <95 Optimal > 95 Prevalence Ratio 
(95%CI) 
χ² p value
2 day recall 
n=93 
 
 
 n (%) 
6 (6) 
n (%) 
87 (94) 
   
<   6km 4 (8) 45 (92) 1.79 
(0.34 -9.33) 
0.497* 0.39 
> 6km 2 (4) 42 (92)    
30 day recall 
adherence n=97 
 
 
 n (%) 
44 (45) 
n (%) 
53 (55) 
   
<   6km 27 (53) 24 (47) 1.43 
(0.90 – 2.26) 
2.46 0.116 
>6 km 17 (37) 29 (63)    
Pill count 
n = 95 
 
 
 n (%) 
25 (26) 
n (%) 
70 (74) 
   
<   6km 19 (38) 31 (62) 2.85 
(1.24 – 6.50) 
7.353 0.006 
> 6 km 6 (13) 39 (87)    
Composite 
adherence 
n = 97 
 
 
 n (%) 
35 (36) 
n (%) 
62 (64) 
   
<  6km 24 (47) 27(53) 1.96 
(1.08 – 3.55) 
5.56 0.018 
> 6km 11 (24) 35 (76)    
* Fischer exact test used 
 
5.2.6. AGE / DURATION OF ARV TREATMENT  
Age   was dichotomised by using the mean age (36 years) as the cut off point. There was 
no significant association between age and adherence with any of the adherence measures 
was not significant at p = 0.05 level of significance.  Similarly, no significant association 
was observed between duration of ARV treatment when dichotomised using the mean   
(20 months) as the cut off point and any of the adherence measures. 
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5.3. SUMMARY 
Ninety –seven participants were included in this study, of which 75% were female. The 
mean composite adherence rate was found to be 95.1% while the proportion of the 
patients who achieved adherence of 95% and above was 64%. Identified barriers to 
adherence included forgetfulness, lack of food and patients being away from their pills.  
The facilitators identified were counselling and treatment supporters. Having knowledge 
of the consequences of failing to take HAART as prescribed ( p = 0.03)  was found to be 
significantly associated with adherence. In addition, increasing distance from home to the 
hospital was found to be significantly associated with non adherence (P = 0.018).   
The next chapter will discuss the key findings within the context of the study setting. 
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CHAPTER 6  
DISCUSSION  
The aim of this cross-sectional study was to provide baseline data on adherence levels 
and factors associated with adherence among patients receiving HAART from Rundu 
Hospital, a public health facility in Namibia. To the author’s knowledge, this study is the 
first to attempt to measure adherence levels and identify factors affecting adherence 
among patients on HAART in Namibia since the inception of the ART program in 2003. 
It is expected that this information will be useful in facilitating the development of 
appropriate intervention strategies to enhance adherence to HAART in this and similar 
settings in Namibia.  
 
6.1. SOCIO – DEMOGRAPHIC CHARACTERISTICS 
A total of ninety – seven patients on HAART participated in the study with a female to 
male ratio of 4:1. This is almost similar to the female to male ratio of 3: 1 of the 1300 
patients on HAART at Rundu Hospital (MOHSS, 2007). This ratio is notably higher than 
the female to male HIV prevalence ratio in Namibia which is 2: 1 (UNAIDS 2008). 
However, the female to male ratio found in this setting  is consistent with other studies in 
Southern Africa where relatively  high female to male ratio of patients on HAART in 
comparison  to the  gender HIV prevalence ratio have been observed  in Zambia, Malawi  
and South Africa ( Stringer et al, 2005: Zacharia et al, 2005: Coetzee et al, 2002). This 
situation may be attributed to women gaining more access to HIV testing as part of 
antenatal care in the Prevention of Mother to Child Programme (PMTCT). In addition, 
other women friendly services like family planning and the general greater use of health 
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facilities by women might also impact on women accessing HIV testing and subsequent 
HAART. Obviously, there are other societal factors related to accessing HAART which 
also need to be taken into consideration. The current situation at Rundu Hospital, 
however, points to the fact that further work needs to be done to explore the reasons for 
the low uptake of HAART by men in this area and to look at ways of bringing them into 
ARV treatment programmes.   
    
6.2. ADHERENCE LEVELS  
The results found a mean composite adherence of 95.1% using the three adherence 
measures: two day self report, 30 day self report with visual analogue scale and pill 
counts. This means that 95% of all the pills that should have been taken by the patients 
were taken. However, this seemingly high mean adherence rate should not give rise to 
complacency as it was not matched by the proportion of patients who achieved 95% and 
above adherence levels. Indeed, the proportion of patients achieving optimal adherence 
(> 95%) was only 64%. This finding highlights the disturbing fact that more than a third 
of the patients on HAART at Rundu Hospital had sub optimal adherence rates and 
approximately 4% of these patients had adherence levels of   less than 85%. The 
implications for this are that a large number of patients on HAART may not be getting 
the full benefits of their treatment and might even be facing the risk of developing drug 
resistant forms of HIV.  
 
The adherence rates found in the present study were considerably lower than those 
reported by Mills et al (2006), in a meta-analysis of studies in Sub Saharan Africa. This 
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meta- analysis found that 82% (95% CI 73-90) of the patients on ARVs in the region had 
achieved optimal adherence levels in studies that defined optimum adherence as 95% and 
above. However, the clinical settings of the studies reported in the meta- analysis were 
not stated and so might have been clinical trials or clinical settings that were different 
from those of the current study which might account for the higher adherence levels 
reported from these studies. 
 
However, a number of studies conducted in Sub-Saharan Africa in similar clinical 
settings to the present study, reported higher proportions of optimally adherent patients 
than the current study. For instance, a study conducted in a public hospital in Nigeria 
reported that 85.1% patients achieved adherence levels of 95% and above (Abah et al, 
2006). A similar study conducted in a public hospital in Cote d’Ivoire reported that 
74.3% of the patients were optimally adherent (Diabate, Alary & Koffi, 2007). In 
southern Africa, a study conducted in a rural hospital in Zambia reported that 83.7% of 
the patients achieved adherence levels of 95% and above (Carlucci et al, 2008).   
These findings suggest that higher adherence levels than those achieved in the current 
study are possible in similar clinical settings in the region.   
 
One of the reasons for the relatively low proportion of patients on HAART who achieved 
optimal adherence at Rundu Hospital may be related to lack of measuring adherence at 
the hospital. Although pill counts are conducted at the hospital, they are usually 
announced so adherence measurement may not be accurate due to pill dumping. In 
addition, the pharmacy usually has no records of the pills taken home as this information 
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is recorded on the patients; cards or pill containers. This indicates lack of proper 
monitoring of adherence which could result in non adherent patients not being identified 
and consequently not receiving any adherence support. The findings of this study 
certainly emphasize that there is an urgency to improve adherence among the patients on 
HAART at Rundu Hospital. 
 
6.3. ADHERENCE MEASUREMENT TOOLS  
The challenges of measuring adherence are compounded by the lack of a gold standard, 
resulting in the use of a number of different strategies to assess adherence. This study 
used three measures: 2 day recall using a sun and moon chart, 30 day self report using a 
visual analogue scale and pill counts, and then a mean composite score was computed. 
The adherence measures were similar to those used in other recent studies conducted in 
Sub- Saharan Africa (Irunde et al, 2006: Kgatlwane et al, 2006). Although each of the 
three methods had advantages and limitations, overestimation of adherence was 
associated with all the three methods.   
 
However,  the use of the three methods together, facilitates  the  measurement of different 
dimensions of adherence and are  also  useful  in  identifying  patients who  might be   
less adherent over longer  periods of time. The brief period of the two day recall allowed 
the measurement of dosing interval adherence which may not have been accurate with 
longer reporting periods (Wagner & Miller, 2004). The 30 day self report and the pill 
counts on the other hand, had longer reporting periods which   provided   room for 
sufficient variability in adherence. These two characteristics demonstrate the 
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effectiveness of these adherence measuring tools in helping to identify the non adherent 
patient in a clinical setting. In addition, some studies conducted in Sub Saharan Africa 
have validated the use of these three adherence measures (Oyugi et al, 2004: Steel, 
Nwokike & Joshi, 2007). The use of the beads as the visual analogue scale might be time 
consuming and a line could be a more practical scale for routine use. Nonetheless, the 
simplicity, relative ease of administration and the low cost of these adherence 
measurement tools in this study illustrate their utility in measuring adherence in a clinical 
setting in a resource limited environment.  
 
6.4. BARRIERS OF ADHERENCE TO HAART 
As a very high level of adherence is required in order for HAART  to achieve the 
intended  treatment benefits, it is critical to have a clear understanding of the factors that 
influence the patient’s ability to comply with the treatment requirements so as address 
them  and thus  enhance adherence to HAART  (Chesney, 2000: Bangsberg et al ,2000).  
 
The present study explored some factors that impede or facilitate optimal adherence to 
HAART among the patients at Rundu Hospital. Although all the ninety- seven 
participants mentioned the factors that facilitated them to take their medication as 
prescribed, only 49% gave reasons for missing doses as the rest self reported 100% 
adherence. Thus a quantitative study involving a larger sample of participants would be 
required to explore the barriers to adherence further. 
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The three main reasons that participants gave for missing doses of medication were 
forgetfulness (28%), lack of food (13%) and being away from their pills (11%). The most 
common reason, forgetfulness was also mentioned by 6% of the participants as a reason 
for missing their doctors’ or pharmacy refill appointments. Forgetfulness has been cited 
as a barrier to adhering to HAART in both resource limited and resource rich settings 
(Mills et al, 2006b). However, the reasons associated with forgetting might be different in 
different settings and need to be explored further.  
 
6.4.1. FORGETFULNESS AND KNOWLEDGE OF ART 
Forgetfulness may be related to being away from pills, which was another reason given 
for missing doses. This barrier, which was cited by11% of the participants, was 
associated with the patients being from home and thus finding themselves without their 
medication when the dose was due. This barrier to adherence in HAART has also been 
reported by other adherence studies in the region (Weiser et al, 2003: Nwokike, 2005). 
Underlying reasons for not taking medication with them may have been forgetfulness, 
failure to incorporate adherence into personal schedules or avoiding taking medication in 
front of other people. Some of these issues could be explored further and could be 
addressed by patient counseling.  
In this study, knowledge of the consequences of failing to take HAART medication as 
prescribed was found to be significantly associated with being highly adherent and is 
consistent with the findings reported in Botswana (Kgatlwane, et al, 2006).  A possible 
reason is that knowledge of HIV and ARVs reinforces the patients’ belief in the 
effectiveness of HAART which in turn may be a motivation for high adherence. 
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The Namibian ART guidelines recommend continuous counseling to patients on HAART 
in order to support their adherence behavior. This recommendation can be supported by 
adherence studies conducted in the region that identified counselling as a correlate of 
adherence (Muganzi,Bondo, Drana & Biryeni, 2004 : Nwokike 2005).  However the 
findings of the study suggest that the counselling provided to patients on HAART at the 
hospital may be inadequate as demonstrated by the fact that counseling was reported as 
an adherence facilitator by only 11% of the participants. In addition, the finding that more 
than a quarter of the participants did not know the consequences of failing to take their 
HAART as prescribed , may be an  indicator of  the quality  of adherence counseling 
given to  the participants as knowledge of HAART is imparted to the patient through 
counseling. It is important to note that counselling should not just be provided at the 
commencement of HAART but should be conducted continuously, so as to identify and 
address factors that affect adherence with time.  
   
 A surprising finding was that, although thirty two participants reported having 
experienced side effects, only one cited missing doses due to side effects, which may 
suggest that adequate counseling on side effects is provided. This finding which was 
consistent with   reports from other studies in Sub Saharan Africa (Weiser et al, 2003: 
Akam, 2004) and may be either due to the side effects being temporary, or to the 
participants’ perception that the severity of the side effects was less in relation to the 
treatment benefits, which in turn may be as a result of counseling.    
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6.4.2. LACK OF FOOD 
Lack of food was also given as a reason for missing doses by 13% of the participants in 
the present study.  This barrier has been cited by adherence studies in Botswana, 
Tanzania and Uganda (Weiser et al 2003: Irunde et al, 2006:  Nakiyemba et al, 2006).  
This barrier may be due to an increased appetite as patients improve with HAART use or 
to non availability of food because the patient is too weak to work, an issue related to 
poverty.  HAART and nutrition are closely related and this study has again highlighted 
that provision of adequate nutrition is an area that needs attention in patients attending 
Rundu Hospital  
 
6.4.3. LACK OF TRANSPORT MONEY 
The finding that none of the participants cited running out of medication as a reason for 
missing doses suggests a regular drug supply at the hospital. Lack of transport money as a 
barrier was reported by 22% of the participants who missed their appointments and the 
finding that more than one in every ten of the participants lived over 50 kilometers away 
from the hospital are aspects that are related to costs of obtaining HAART.   
Costs and travelling long distances were barriers that were reported in studies from 
developing countries by the meta-analysis by Mills et al (2006 b).  In addition, transport 
costs were also cited as a barrier to adherence in other studies in sub-Saharan Africa 
(Mukabatera, 2004: Nakiyemba et al, 2006). A possible reason is the lack of reliable 
transport to the hospital which could impact on the travelling costs. This suggestion is 
supported by the findings during the pilot study that reliable transport was a constraint 
among the participants. 
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The implication of this barrier is that despite the availability of HAART free of charge, 
some other cost factors still impede adherence to HAART in sub- Saharan Africa. This 
barrier highlights the fact that both availability and accessibility issues should be 
addressed to ensure adherence to HAART with the scaling up of ART programs in 
resource limited settings. 
 
6.5. FACILITATORS OF ADHERENCE TO HAART 
Over half of the participants reported that they used devices like cell phones and radios to 
remind them to take their doses which is consistent with findings from other studies in 
the region (Kgatlwane, et al,  2006: Irunde et al ,2006: Nakiyemba et al , 2006).  
Treatment supporters were also mentioned as an adherence facilitator by the participants 
in the present study. The value of treatment supporters as an adherence facilitator has 
been reported in other studies in the region (Nwokike, 2005: Nachega, 2006). However, 
the finding that less than 20% of the participants reported their treatment supporters as 
adherence facilitators was disappointing. This is despite the fact that the Namibian ART 
guidelines require every patient on HAART to have a treatment supporter and raises the 
question of the role of the mandatory treatment supporter in adherence. A possible 
explanation for this finding is that most patients identify a supporter only for the purposes 
of presenting someone to the hospital so that they can be started on treatment. This raises 
the importance of clearly defining the on-going role of the treatment supporter in 
adherence to both the treatment supporter and the patient.  
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6.6. FACTORS ASSOCIATED WITH ADHERENCE   
 
In addition to measuring the barriers and facilitators of adherence to HAART, the study 
also analyzed the association between these factors and adherence to HAART.  
Knowledge of the consequences of failing to take HAART medication as prescribed was 
found to be significantly associated with adherence (p-value = 0.03), while increasing 
distance to the hospital was found to be associated with non adherence (p- value = 0.018). 
In addition, being male was found to be significantly associated with adherence (p= 
0.04).   Conversely, marital status, education level and age were not significantly 
associated with adherence. Other factors that were found not to be significantly 
associated with adherence were disclosure of HIV status, ART regimen and duration on 
ART.   
 
The finding that having knowledge of the consequences of failing to take HAART 
medication as prescribed was significantly associated with being highly adherent is 
consistent with the findings reported in Botswana (Kgatlwane, et al, 2006).  A possible 
reason is that these reported consequences could be an indication of belief in the 
effectiveness of the ARVs which subsequently may be motivation for high adherence.  
 
Similarly, the finding that increased distance was significantly associated with non 
adherence is consistent with findings from other studies in Sub Saharan Africa (Weisser 
et al , 2003: Nakiyemba et al,  2006). A possible reason is that transport costs are likely to 
be directly proportional to distance which may present a constraint to travel to the 
hospital for medication refills.  In addition, the lack of reliable transport to the hospital as 
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reported during the pilot study may increase as the distance from the hospital increases. 
These suggestions may be supported by the finding that more than 10% of the 
participants had to travel more than 50kms to the hospital.  
 
The finding that being male was significantly associated with adherence despite  the fact 
that the proportion of males among the participants was much lower than that of females 
may suggest that the few males on ART had strong motivation to be on the programme 
and as such were motivated to be adherent. However a qualitative research could provide 
more clarity on this finding. 
 
The findings that marital status, age and education level were not significantly associated 
with adherence are consistent with other studies in Sub Saharan Africa (Diabate, Alary & 
Koffi ,2007). Correspondingly, the findings that reported side effects were not 
significantly associated with adherence were consistent with findings from other studies 
in the region (Weiser et al, 2003: Nakiyemba et al, 2006).  On the other hand, the 
findings that ART regimens are not significantly associated with adherence are not 
consistent with other studies in the region, (Laniece et al, 2003: Nwokike, 2005). A 
possible reason is that the study participants were all on first line regimens and such may 
not have had complicated dosing requirements.  
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SUMMARY 
As this is the first study to attempt to measure adherence and identify factors that affect 
adherence among patients on HAART in Namibia, the findings of this study provide 
baseline data that could be useful in designing practical interventions to enhance 
adherence in Rundu Hospital and other similar settings in Namibia. In addition, the 
methodology used in this study can also be used to measure adherence to HAART in 
other similar hospitals in Namibia. The study also provides groundwork for qualitative 
and quantitative studies to explore and quantify these factors further.  
 
 
STUDY LIMITATIONS   
The low response rate on the question on barriers to taking medication as prescribed is a 
limitation in this study and thus a quantitative study would be required to explore the 
barriers in depth. In addition, further qualitative studies would be beneficial to explore 
the barriers and facilitators related to adherence and the ways that they interact to 
influence adherence. 
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CHAPTER 7 
7.1. CONCLUSIONS 
This study is the first study of its kind in Namibia and the findings have provided useful 
baseline data on the adherence rates and some insights into the major factors that affect 
adherence among patients on HAART at Rundu Hospital. However further qualitative 
and quantitative studies are required to explore the factors influencing adherence further. 
 
The study found that the mean adherence level among patients on HAART at Rundu 
Hospital was 95.1%, while the proportion of patients who achieved adherence levels of 
95% and above was 64%. Despite the reported high average adherence level, just less 
than two thirds of patients achieved optimum adherence levels; consequently more than a 
third of the patients on HAART at Rundu Hospital run the risk of poor health outcomes 
and also developing drug resistant forms of HIV.  
 
Thus, in view of the individual and public health implications of non adherence, these 
findings indicate an urgent need to improve adherence levels among patients on HAART 
at Rundu Hospital. This may in part be achieved by measuring adherence levels of 
patients on HAART, in order to identify both non adherent patients and provide targeted 
adherence support, and also identify ART Programmes that need further investigation. 
The higher adherence levels reported in similar clinical studies in other sub- Saharan 
African settings point to the feasibility of achieving greater adherence in this setting. 
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Similarly, in light of the scaling up of the ART program in Namibia, there is need to not 
just monitor the levels of adherence, but also to identify and address factors that affect 
adherence so that the increasing number of patients receiving HAART can achieve the 
full intended benefits of HAART.  The main barriers to adherence identified in this study 
were forgetfulness, lack of food and transport costs. The study found that more than one 
in every ten people had to travel a distance of 50 kilometers or more to the hospital. In 
addition, distance from home to the hospital was found to be significantly associated with 
adherence, with adherence decreasing with increasing distance. This barrier indicates that 
although HAART is available at Rundu Hospital free of charge, there are still issues of 
accessibility to many patients in terms of transport costs. These barriers have been cited 
in other studies in Sub-Saharan Africa (Mills et al, 2006b: Kgatlwane et al, 2006: 
Nakiyemba et al, 2006). Another cost related barrier to adherence among the patients on 
HAART at Rundu was the lack of food. As patients on HAART improve, so does their 
metabolism, resulting in more demand for food.  In addition, good nutrition is required 
for the restoration of the immune system, and so addressing a regular supply of food to 
patients on HAART was also found to be an important aspect of the ART Programme. 
 
The role of treatment supporters and counseling were found to have a positive impact on 
adherence to HAART in this setting. Knowledge of consequences of not taking HAART 
as prescribed, which is closely linked with counseling, was found to be significantly 
associated with adherence in this study. These facilitators to HAART have been 
identified in other studies in Sub Saharan Africa and further developments in these 
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services would add value to the ART Programme in Rundu Hospital (Nwokike, 2005: 
Mukabatera et al, 2004. 
 
7.2. RECOMMENDATIONS 
In accordance with the findings of this study, the following recommendations should be 
considered to assist in improving adherence among patients on HAART at Rundu 
Hospital.  
 
• Programmes that target men for HIV testing and ARV treatment should be 
developed. Similarly, the factors that impede men taking up testing and treatment 
either at health system or society level should be explored. 
• A system to measure adherence levels should be instituted at Rundu Hospital.  
• The capacity of health facilities located more than 6 kilometers away from the 
hospital should be increased to facilitate provision of HAART. 
• The on-going supportive role of the treatment supporter in adherence should be 
defined to both the patients and the treatment supporters  before  commencement 
of HAART  
• A counseling protocol should be instituted at the hospital.  
• The provision of food to patients on HAART who require such assistance should 
be investigated with relevant stakeholders 
• Further studies, involving both quantitative and qualitative methods, should be  
conducted to quantify and further explore the factors that influence adherence in 
this setting. 
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APPENDIX 1  
 
 
INFORMATION SHEET 
 
Adherence to HAART and its major determinants in adult patients in Rundu 
Hospital, Namibia.  
I am Patricia Komu, a student studying at the University of the Western Cape. I am 
getting information from patients on HAART.I am collecting information related to 
adherence to HAART in Rundu. I would like to ask you some questions, which will take 
about 20 minutes of your time and I would like you to participate in the study. 
  
What is the study about? 
Adherence to HAART is the most important aspect of this treatment because if the 
patients do not take their medication properly, the medicines do not work. However, 
HAART is a complicated regimen that is life long and sometimes it is difficult for 
patients to take their medications as required due to some factors. This study will identify 
factors that affect adherence in our community. This will assist in providing quality 
adherence support to patients on HAART so that they can take their medications as 
required in order to achieve the benefits of their treatment.  
 
Who are the participants? 
The participants are patients on HAART in Rundu Hospital in Namibia. These patients 
should be 18 years and above and should have been on HAART for more than three 
months. 
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What will I be asked to do if I agree to participate? 
The researcher will ask questions about yourself and experiences you have had with 
taking your HAART medication. You will also be asked about your ability to take 
medication as prescribed by the doctor and any problems or benefits you have 
experienced with the HAART medication. Information on number of pills and type of 
drugs will be obtained from your patients’ health passports and then the pills remaining 
will be counted     
. 
Would my participation in this study be kept confidential? 
We will keep your personal information confidential.  To help protect your 
confidentiality, all the information collected will be confidential and your name will not 
be included on the surveys and other collected data. A code will be used in the survey and 
the collected data and only the researcher will have access to it. If I write a report or 
article about this research project, your identity will be protected 
 
What are the risks of this research? 
There are no known risks associated with participating in this research project 
 
What are the benefits of this research? 
This research is not designed to help you personally, but the results may help the 
investigator learn more about factors affecting adherence to HAART so as to provide 
better adherence support to patients on HAART. We hope that, in the future, other people 
 
 
 
 
92 
 
might benefit from this study through improved understanding of adherence issues to 
HAART.  
 
Do I have to be in this research and may I stop participating at any time?   
The study is completely voluntary. You may withdraw from the study at any time, 
without having to give a reason or may refuse to answer a question should you wish to. 
Your treatment will not be influenced in any way by your decision to participate or not. 
 
Is any assistance available if I am negatively affected by participating in this study? 
Yes, if you require assistance, you will be referred to a counselor or a clinician who will 
assist you. 
What if I have questions? 
This research is being conducted by Patricia Komu of the School of Public Health at the 
University of the Western Cape.  If you have any questions about the research study 
itself, please contact _ Mrs. Patricia Komu at: Rundu Hospital Flats Tel 066 256327  
Should you have any questions regarding this study and your rights as a research 
participant or if you wish to report any problems you have experienced related to the 
study, please contact:  Hazel Bradley at Tel : 27219592630 cell 0722979932 
Head of Department: 
Dean of the Faculty of Community and Health Sciences:  
University of the Western Cape 
Private Bag X17 
Bellville 7535         
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APPENDIX 2 
 
INFORMED CONSENT FORM 
 
Title of Research Project: Adherence to HAART and its major determinants in 
adult patients in Rundu Hospital, Namibia.  
 
I freely and voluntarily agree to participate. My questions about the study have been 
answered. I understand that my identity will not be disclosed and that I may withdraw 
from the study without giving a reason at any time and this will not negatively affect me 
in any way.   
 
Participant’s name……………………….. 
Participant’s signature……………………………….                                   
Date……………………… 
Should you have any questions regarding this study or wish to report any problems you 
have experienced related to the study, please contact the study coordinator: 
Study Coordinator’s Name: Patricia Komu  
Rundu State Hospital  
P.O Box 47 Rundu. 
Telephone: (066) 256327- 
Cell: 0812776274 
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APPENDIX 3 
INFORMATION SHEET (RUKWANGALI TRANSLATION) 
 
 
Esikiso –somo lyo kunwa mutji go HIV (HAART) ntani kwakara sininke so sinene 
so kudidilikira mo vaveli w ova kurona mo sipangero za Rundu, mo Namibia. 
 
Ame nyame Patricia Komu, mu nasure ani lirongere ko nkure sure zo nene ezi ava 
tumbura asi Western Cape. Ame kua hara ku gwana mapukururo ko vaveli ava vana kara 
po no mutji do HIV ndi po HAART. Ame kuna ku ponga yika mapukururo go ku haena 
esikisomo lyo kunwa mutji go HIV (HAART)mo Rundu. Ame kuna hara kukupura 
mapuro , aga naga kwata siruwosoku sika ko no minute no murongo mbali so ru veze 
rweni, ntani  ova hara olihae sermo me konakono. 
 
Ekonokono lyo ku hamena ko sinke? 
Esikisomo lyo kunwa mutji go HIV (HART) yiso sininke po so mulyo unene ko wowu 
uhaku, morwa nsene asi vaveli kpi vana kunwa no mutji dawo nawa, no mutji kapi tadi 
rugana. Nampili ngoso,no mutji do HIV ndi HAART kwa kara no udigu wago ado de 
paru mudima. Ntani hena udigu ko vaveli kunwa mutji dawo nomu va heap ku dinwa 
,morwa po dili no kondo dimwe. Ekunakono eli nail dimurura no konda dimwe edi adi 
ninkisa asi mbunga mponganasa ndi nkarapamwe vapire kusikisano kunwa no mutji.Eyi 
nayi tu vatera mo ku gava mulyo ge sikisomo, mo kuvatera vaveli ava vana kara po no 
mutji do HIV (HAART)yip ova new no mutli dawo momu ya wapera, yipovagwanesepo 
mauwa nsi go wa haku wawo. 
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Wolye va lihamesilimo?    
Valihasilemo va veli ava vakara po no mutji do HIV (HAART) womo sipangero za 
Rundu mo Namibia. Ava va  veli va kona ku gwa nesa no mvhura murongo nah ambo 
tatu (18) si kwadwise ntani awe hena kwa kara po no mutji do HIV (HAART)kupita kana 
makwedi gatatu. 
 
Yisinke na va vhura kupurange eyi na nirugana nseneame nina pura 
kulihameserano? 
Mukonakoni na vhura kuku pura epuro lyo kuhamena kwa nyamoge. Ntani enongonono 
eliwa kara nalyo po kunwa no mutji do (HAART). Ntani nava kupura udivi woge po 
kunwa mo mutji mo mu adi tjanga ndokotora ntani nkenye udigu ndi mauwa aga wa 
nongononamo yokuhamena mutji go HIV (HAART). Mapukururo go kuhamena asi 
“nopera dingapi ntani marudi go no mutjimusinke. Oyo kuvhura kuyigwana mo no 
mbapira do sipangero do vaveli woge ntani no pera dina hupuko da  ov kudi varura. 
 
Kuvhura Elihamesere molyange Mekonakono eli valiture likare mehoramo ndi? 
 
Ose natu gatura mapukururo goge gakare gana horama. Kwatu ogu natuga tantera, mo 
kuvhura kuvantantera ehoromano lyoge, mapukururo nagenye aga nakuponganyika, 
tagakara ge horamo ntani Edina lyoge kapi natuli ruganesa mekonakono eli ndi 
makonakono gamwe. Nomora yizo ngava ruganesa me konakono eli ntani maponganyiko 
aga tunapura apa, ko mukonakoni gelike yige go kuvhura kukara no mpito zoku vhura 
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kugatara. Nsene ame tani tjanga siparatjangwa so kuhamena ekonakono lyo proyeka. 
Edina lyoge nganiligamen / kulipoperea. 
 
Siponga musinke sakaramo mweli ekonakono? 
Kutupu siponga sa divikwa se lihameseremo, momakonakono go proyeka ezi. 
Uwa musinke wakaramo me konakono eli? 
Ekonakono eli kapi valitulisilapo asi, likuvatere pa untu woge, nye yitundamo kuvhura 
yivatere mukonakoni mokudiva yo yinzi yo kuamena n konda edi adi ninkisa asi epiro ku 
sikisamo lyo kunwa no mutji do HIV (HAART) yipo tugave esikisomo lyo hasa, no 
kuvatera vaveli ava vanakara po no mutji do HIV (HAART). Ose twasi huguvara asi; “ko 
meho oko vantu vamwe kuvhura vaka gwanenemo ma uwa me konakono eli. Kupitira mo 
kuwapukurura no kuzuvhako yoku hamena esikisomo kunwa no mutji do HIV (HAART). 
 
Kuvhura nikare me konakono eli, ndi kuvhura nihageke mokulihame seramo 
nkenye ruveze? 
Ekonakono eli lya gogu ana hara kulihameseramo. Kuvhura otundemo mekonakono eli 
nkenye ruveze, wa hana kugava konda ndi kuvhura o nyoke kulimburura epuro nsene ono 
yihara nyamoge. Kapi tayizona gura uhaku woge morwa asi ove onotokora asi ove  to 
hameno ndi kapi ono kuhame namo. 
 
Pozili mbatero za karapo nsene asi “ame tayi gumunge momudona 
mokulihameseramo me konakono eli ndi? 
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Nhi, nsene ono  ov mbatero, kuvhura vakutume  ova ehungomwenyo ndi kwa 
ndokotora ogo na vhura kuku vatera. 
 
Ngapi nsene nina kara nepuro? 
Konakono eli kwali rugana Patricia Komu goko sure zo nkarapamwe zou uhaku ko nkuru 
sure za Western Cape. Nsene ona kara no mapuro nkenye goku hamena ekonakono eli 
nakanderere gwanekera no mugolikadi (Mrs) Patricia Komu ko sipangero za Rundu ko 
nzugo ndi ngodi ezi 066 256327. 
Kuvhura una kara no mapuro nkenye go kuhamena eknakono eli ntani wa kara no no 
nkondo asi “Omu konakoni, mu lihamesilimo ndi nsene ono hara kugava nkenye 
maudigu aga wa gwanekera nago, go kuhamena kekonakono, nakanderere gwanekera na 
Hazel Bradley ko ngodi ezi; +27219592630 funguna zoko mahoko +27 722979932, 
Mukurona go ruha, 
Mukurona go nkuru sure zo nkarapamwe no uhaku nowu nkurungu Nkuru sure za 
Western Cape, Nsako zo Posa x17 Bellville 7535.  
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 APPENDIX 4 
INFORMED CONSENT FORM (RUKWANGALI TRANSLATION ) 
 
Ntumbiso ze konakono proyeka: Esikoso lyo kunwa mutji go HIV (HAART) ntani 
kwakara sininke sosinene so ku didilikira mo vaveli wova kurona mo sipangero za 
Rundu, mo Namibia. 
Ame ya mahukire nge no kulizambera ku hamenamo. Mapuro gange go ku hamena 
ekonakono eli vana ga limburura. Ame nasi huguvara asi Edina lyange kapi ngava. 
Lipwagesa ntani ame kuvhura ku hageka mo makonakonoaga. Kupira kugava nkenye 
konda pwa nkenye ruveze ntani kapi nayi gumange mo udona mo ruhapeke. 
 
Edina lyo Muhamenimo…………………………………………………. 
Edina supipiko   lyo Muhamenimo……………………………………… 
Ezuva …………………………………… 
Kuvhura ono kara na mapuro nkenye goku hamena ekonakono eli, ndi nsene ono hara 
kugava nkenye maudigu aga wa gwanekera nago go kuhamena kekonakono. Nakanderere 
gwanekera no mu kwatakanesi ekonakono.Nakanderere gwanekera no mu kwatakanesi 
ekonakono: 
Edina lyo mukwatakanesi ekonakono: Patricia Komu  
Sipangero za Rundu 
Simbangu posa 47 Rundu 
Ngodi: (066)256327 
Ngodi zoko mahoko: 0812776274 
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APPENDIX 5 
 
 
Adherence Measurement for ART users questionnaire 
 
 Date ______________   Respondent No._____    ARV  NO:------------         
 
1. Date of birth   M______Y_________ 
 
2. Sex  
   a). Male                      b). Female  
 
3. Marital Status 
 
  a). Single                             b). Married /cohabiting                    
                 
 c) Divorced                            d) Widowed                                  
 
  
 
4. What is the highest standard that you have passed at school? 
      
a) No schooling                           b). Grade 4 and below 
 
 
   c). Grade 5 to 7                        e). Grade 8 to 12                          
 
 
   f) Tertiary   
 
 
5. Where do you live? ------------------------- nearest clinic/ health centre------- 
 
 
 
6. When did you start HAART?  M_________ Y_________ 
 Interviewer should countercheck answer with records from patients’ passport    
 
7. Have you experienced any side effects with this medication? 
 
 a). Yes                     b). No 
 
8. What do you think would happen in your body if you skipped your ARV 
medicine? ( pls tick one) 
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a). Viral load increases        b). Virus becomes resistant (drugs don’t work)     
 
c). Health deteriorates            d) Don’t know        
 
e). other (pls specify) 
 
9. Apart from your treatment supporter, have you disclosed your HIV status to 
anybody else ? 
 
a). Yes                         b). No 
 
 
10.  If yes to Q9 who? 
 
a).  Brother/sister                b). Parent                                     c).Partner  
 
d) Child                      e). other (pls specify) 
 
 
 
11. Many people find it hard to take all their HIV medicine exactly as prescribed. 
Which of the following reasons has caused you to skip your medicines or take them 
later than required ? please feel comfortable o answer this question truthfully ( tick 
Max 3) 
 
a).Forgot                        b). No food                    c) Medicine exhausted  
 
d). Tired with the medicine            e) Did not have pills with you 
 
f). Reacted to the medicine           g). Shared pills 
 
h).Feeling you had to hide medication from those around you 
 
i). Did not understand instructions  
 
j). Alcohol use                                 k) Lack of care/support  
 
l). Others (specify pls) 
………………………………………………………………………… 
 
 
12. What is it that helps you to take your HIV medicine regularly as prescribed? 
(Tick maximum 2) 
 
a). Treatment supporter                    b).counselling       
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c). reminders (radio, cellphone, etc)         
 
d). other (pls specify) 
 
13. Many people find it difficult to collect their medicines or attend appointment on 
the date given by the doctor. Which of the following reasons has caused you to miss 
an appointment or not to collect your medicines ?  ( tick max 3) 
 
a.). Forgot    b). Ill/ not feeling well enough        c). still had medicines left  
 
d). no money for transport          e). tired with medicine                              f). did not have 
anyone to travel with me  
 
g). Could not have time off work     h). did not want to lose a days pay 
 
i). other (pls specify) 
 
14. Can I see your medicine please? Complete names of the medicines. Interviewer 
should check containers and patients health passport  
 
 
a). D4T/3TC  + NVP            b). AZT/3TC + NVP        c). D4T/3TC + EFV                                        
 
d)AZT/ 3TC + EFV              e). TDF + 3TC + EFV       f). TDF+ 3TC + NVP 
 
 
 
15. 30 day recall using visual analogue. 
 
 Ask patient to pour out one lot of beads ( representing all the pills they would take in 
any give month . Note: separately for each drug). A glass full of beads is marked with 
a  0-10cm line. After pouring beads to an empty glass, estimate pills not taken by looking 
at the mark of beads remaining in the glass. 
 
Drug A________cm        Drug B________cm          Drug C______cm  
 
Composite_______________________cm 
 
 
16.  2 day recall using sun and moon chart
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Mark “X” on each 
line the time when 
you took your 
Medicine Yesterday? 
6 
am 
7 
am 
8 
am 
9 
am 
10 
am 
11
am 
12 
 
 
1 
pm 
2 
pm 
3 
pm 
4 
pm 
5 
pm 
6 
pm 
7 
pm 
8 
pm 
9 
pm 
10 
pm 
11 
pm 
 
12 
Mo
rn 
     
Mi
dd
ay 
     
Ev
e 
 
 
 
    
Ni
ght 
Drug A                    
Drug B                    
Drug C                    
Drug D                    
 
 
 
Mark “X” on each 
line the time when 
you took your 
Medicine the  
Day before 
Yesterday? 
6 
am 
7 
am 
8 
am 
9 
am 
10 
am 
11
am 
12 
 
 
1 
pm
2 
pm
3 
pm 
4 
pm 
5 
pm
6 
pm
7 
pm
8 
pm
9 
pm
10 
pm
11 
pm 
 
12 
M
orn 
     
Mi
dd
ay 
     
Ev
e 
     
Ni
ght
Drug A                    
Drug B                    
Drug C                    
Drug D                    
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17. PHARMACY REFILL RECORD pill counts 
 
 Example Drug A Drug B Drug C DrugD 
Drug name(as 
in Q11) 
D4t     
a).Previous 
date issued 
2aug     
b). Qty taken 
home (total) 
66     
c). Qty 
returned 
11     
d). Date 
returned 
1sept     
e). Days since 
last issue 
30     
f). Doses per 
day 
2     
g). Total 
supposed to 
take 
60     
h). Should 
have returned 
b-g 
66-60= 6 
    
i). Pills missed c-h 
11-6=5 
    
j). Percent 
adherence  
g-i/g x 100 
60-5/60 
x100 
    
 
 
……………………………………………………………………………………………… 
 
 
Thank you very much for sharing your experience with us 
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APPENDIX 6 
BIVARIATE   ANALYSIS TABLES 
Table 1: Bivariate analysis of ART Knowledge using adherence in three categories  
 
 Adherence Category    
Adherence measure ART Low Medium High χ² p 
Knowledge < 85% 85 - <95 % >95%  value 
30 day recall  n  = 97 
 n (%) 
20 (21) 
n (%) 
24 (25) 
n (%) 
53(54) 
  
Yes 14(20) 20(28) 37(52) 1.67 0.43*
No 6 4 16   
Pill count n = 95 
 n (%) 
9 
n (%) 
16 
n (%) 
70 
  
Yes 6 15 49 4.04 0.13*
No 3 1 21   
Composite adherence    
n = 97 
 n (%) 
4 
n (%) 
31 
n (%) 
44 
  
Yes 1 26 44 6.69 0.03*
No 3 5 18   
*Fischer exact test 
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Table 2: Bivariate analysis of ART Knowledge using adherence in dichotomous categories  
 
   Adherence Category    
Adherence measure ART 
Knowledge 
Sub 
optimal 
<95 % 
Optimal 
>95% 
Prevalence 
Ratio (95% 
CI) 
χ² p 
value   
30 day recall adherence 
n=97 
  
  
 n (%) 
44(45) 
n (%) 
53(55) 
   
Yes 34 (45) 37(55) 1.11 (0.87 - 
1.44) 
0.35 0.55 
No 10 (39) 16 (61)    
 2 day recall adherence n= 
93 
  
  
 n (%) 
6 (6) 
n (%) 
87 (94) 
   
Yes 4 (6) 64 (94) 0.74 (0.14 -
3.77) 
0.14* 0.65 
No 2 (8) 23(92)    
Pill count n = 95 
  
  
 n (%) 
25 (26) 
n(%) 
70 (74) 
   
Yes 21 (30) 49 (70) 1.20 (0.95 - 
1.51) 
1.21* 0.27 
No 4 (16) 21(84)    
Composite adherence n = 
97  
  
  
 n (%) 
35 (36) 
n (%) 
62 (64) 
   
Yes 27(38) 44(62) 1.09 (0.85 - 
1.38) 
0.43 0.50 
No 8 (30) 18 (70)    
• Fischer Exact Test used 
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Table 3: Bivariate analysis of Gender using adherence in the three categories  
 
 
 Adherence 
Category 
  
Adherence measure Gender 
 
Low Medium High χ² p 
< 85% 85 - <95 % >95%  value
30 day recall adherence 
 n = 97 
 
 
 n (%) 
20 (21)
n (%) 
24 (25) 
n (%) 53(54)   
Female 17(22) 22(29) 37(49) 5.31* 0.07 
Male 3(14) 2(10) 16(76)   
Pill count n = 95 
 
 
 n(%) 
9 (9) 
n(%) 
16(17) 
n(%) 
70(74) 
  
Female 9(12) 13(18) 52(70) 3.19* 0.2 
Male 0 3 9(14) 18 (86)   
Composite adherence  
n = 97 
 
 
 n(%) 
4 (4) 
n(%) 
31(32) 
n(%) 
44(45) 
  
Female 4 (5) 27(36) 45(51) 2.41* 0.12 
Male 0 4 17   
*Fischer Exact test used  
 
 
Table 4: Bivariate analysis of Gender using adherence in dichotomous categories  
 
  Adherence 
Category 
      
Adherence measure Gender Sub optimal Optimal Prevalence  χ² p  
  <95 % >95% Ratio (95% CI)   value
30 day recall adherence 
n=97 
 
 
  n (%) 
44 (45) 
n (%) 
53 (55) 
      
Female 39 (51) 37 (49) 1.27 (1.03 - 1.56) 3.97 0.04 
Male 5 (24) 16 (76)       
2 day recall adherence 
n= 93 
 
 
  n (%) 
6 (6) 
n (%) 
87 (94) 
      
Female 5 (7) 68 (93) 1.07 ( 0.73 - 1.55) 0.05* 1.00 
Male 1(5) 19(95)       
Pill count 
n = 95 
 
 
  n (%) 
25 (26) 
n (%) 
70 (74) 
      
Female 22 (30) 52 (70) 1.18 (0.97 - 1.45) 1.29* 0.25 
Male 3 (14) 18 (86)       
Composite adherence 
n = 97 
 
 
  n (%) 
35 (36) 
n (%) 
62 (64) 
      
Female 31 (41) 45 (59) 1.22 (1.01 -1.48) 3.37* 0.06 
Male 4 (19) 17 (81)       
*Fischer exact test use 
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Table 5: Bivariate analysis of adherence with median distance as the cut off  
 
  Median distance   = 6 km    
  Adherence Category    
Adherence measure 
distance Suboptimal 
<95 
Optimal > 95 Prevalence 
Ratio 
(95%CI) 
χ² p 
value 
2 day recall n=93 
 
 
 
n (%) 
 6 (6) 
n (%) 
 87 (94)    
<   6km 4 (8) 45 (92) 1.79 
(0.34 -9.33) 
0.497
* 
0.39 
> 6km 2 (4) 42 (92)    
30 day recall adherence 
n=97 
 
 
 
n (%) 
 44 (45) 
n (%) 
 53 (55)    
<   6km 27 (53) 24 (47) 1.43 
(0.90 – 2.26) 
2.46 0.116 
>6 km 17 (37) 29 (63)    
Pill count 
n = 95 
 
 
 
n (%) 
 25 (26) 
n (%)  
70 (74)    
<   6km 19 (38) 31 (62) 2.85 
(1.24 – 6.50) 
7.353 0.006 
> 6 km 6 (13) 39 (87)    
Composite adherence 
n = 97 
 
 
 
n (%) 
 35 (36) 
n (%) 
 62 (64)    
<  6km 24 (47) 27(53) 1.96 
(1.08 – 3.55) 
5.56 0.018 
> 6km 11 (24) 35 (76)    
*Fischer exact test 
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Table 6: Bivariate analysis using composite adherence in 3 adherence categories 
  
   Composite adherence n=97   
  Adherence Category   
Variable Low 
< 85 
Medium 
85 - <95 
High 
> 95 
χ² p value 
  
n (%) 
4 (4) 
n (%) 
 31 (32) 
n (%) 
 62 (64)   
Marital status  
 married/cohabiting 4 (8) 15 (31) 30 (61) 4.09* 0.12 
divorced/single/widowed 0  16 (33) 32(67)   
Education level  
> secondary  2 (4) 17 (36) 29 (60) 0.54* 0.76 
< secondary  2 (4) 14 (29) 33(67)   
Disclosed status  
  Yes 4 (5) 26 (32) 51 (63) 0.86* 0.64 
  No 0 5 (31) 11(69)   
Regimens  
same dosing 2 (3) 28 (35) 50 (62) 4.38* 0.11 
different dosing  2 (12) 3 (18) 12 (70)   
ART knowledge 
Yes 1 (1) 26 (37) 44 (62) 6.69* 0.03 
No 3 (12) 5 (19) 18 (69)   
Reported Side Effects 
Yes 2 (6) 13 (41) 17 (53) 2.52* 0.28 
No 2 (3) 18 (28) 45 (69)   
Gender 
Female 4 (5) 27(36) 45 (59) 2.41* 0.12 
Male 0 4 (19) 17 (81)   
*Fischer Exact test 
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Table 7: Bivariate analysis using composite adherence in dichotomous adherence 
categories  
 
  Composite adherence n=97    
  Adherence Category    
Variable Suboptimal <95 Optimal > 95 Prevalence ratio 
(95%CI) 
χ² p value 
  n (%) 
35 (36) 
n (%) 
 62 (64) 
   
Marital status  
married/cohabiting 19 (39) 30 (61) 1.12 
(0.75-1.67) 
0.31 0.5 
divorced/single/widowed 16 (33) 32 (67)    
Education level  
> secondary  19 (40) 29 (60) 1.16 
(0.78-1.74) 
0.5 0.47 
< secondary  16 (33) 33 (67)    
Disclosed status  
Yes 30 (37) 51(63) 1.04 
(0.87-1.24) 
0.19 0.65 
No 5 (31) 11(69)    
Regimens  
    same dosing 30 (38) 50 (62) 1.06 
(0.89-1.28) 
0.40 0.52 
 different dosing  5 (29) 12 (71)    
ART knowledge 
Yes 27 (38) 44(62) 1.09 
(0.85-1.38) 
0.43 0.50 
No 8 (31) 18 (69)    
Reported Side Effects 
Yes 15 (47) 17 (40) 1.56 
(0.90 -2.73) 
2.41 0.12 
No 20 (31) 45(69)    
Gender 
Female 31 (41) 45 (59) 1.22 
(1.01-1.48) 
3.37* 0.06 
Male 4 (19) 17 (81)    
*Fischer exact test 
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Table 8: Bivariate analysis using 2 day recall adherence in dichotomous adherence 
categories  
 
  2 day recall  n=93   
  Adherence Category   
Variable Suboptimal 
<95 
Optimal 
>95 
Prevalence Ratio 
(95%CI) 
p value  2 
tailed 
  
n (%) 
 6 (6) 
n (%) 
87 (94)   
Marital status  
married/cohabiting 4 (8) 45 (92) 1.29  (0.71-2.35) 0.67 
divorced/single/widowe
d 2 (5) 42 (95)   
Education level  
> secondary  3(6) 44 (94) 0.99  (0.43 -2.26) 1.00 
< secondary  3 (7) 43(93)   
Disclosed status  
Yes 5 (6) 72 (94) 1.01 (0.70- 1.46) 1.00 
No 1 (6) 15 (94)   
Regimens  
same dosing 4 (5) 74 (95) 0.38 (0.08 -1.91) 0.24 
different dosing  2 (13) 13 (87)   
ART knowledge 
Yes 4(6)  64 (94) 0.74 (0.14 -3.77) 0.65 
No 2 (8) 23 (92)   
Reported Side Effects 
Yes 0 31(100) Undefined 0.17 
No 6 (10) 56 (90)   
Gender 
Female 5 (7) 68 (93) 1.07 (0.73 – 1..55) 1.00 
Male     
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Table 9: Bivariate analysis using 30 day recall adherence in 3 adherence categories 
  
   30 day recall adherence n=97   
  Adherence Category   
Variable Low 
< 85 
Medium 
85 - <95 
High 
>95 
χ² p value 
  
n (%) 
 20 
n (%) 
 24 
n (%)  
 53   
Marital status  
      married/cohabiting 11 (22) 11(22) 27(56) 0.38 0.82 
     divorced/single/widowed 9 (19) 13(27) 26 (54)   
Education level  
       > secondary  9 (24) 15(31) 24 (45) 2.16 0.33 
      < secondary  11(22) 9 (18) 29 (59)   
Disclosed status  
       Yes 18 (22) 21(26) 42 (52) 1.59 0.45 
       No 2 (13) 3(19) 11(68)   
Regimens  
     same dosing 19 (24) 19 (24) 42(52) 2.73* 0.25 
     different dosing  1(6) 5(29) 11(65)   
ART knowledge 
     Yes 14 (20) 20 (25) 37 (45) 1.67 0.43 
      No 6 (23) 4 (15) 16 (62)   
Reported Side Effects 
     Yes 11(50) 6 ( 27) 5 (23) 5.6 0.06 
     No 9 (14) 18 (28) 38(58)   
Gender  
     Female 17 (22) 22 (29) 37 (49) 5.31* 0.07 
     Male 3 (14) 2(10) 16 (76)   
 *Fischer exact test 
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Table 10 Bivariate analysis using 30 day recall adherence in dichotomous adherence 
categories  
 
  30 day recall  adherence n=97    
  Adherence Category    
Variable Suboptimal <95 Optimal > 95 Prevalence ratio 
(95%CI) 
χ² p value 
  n (%) 
 44 (45) 
n (%) 
 53(55) 
   
Marital status  
married/cohabiting 22 (45) 27 (55) 0.98 (0.66 -1.46) 0.01 0.91 
divorced/single/widowe
d 
22 (46) 26 (54)    
Education level  
> secondary  24 (50) 24(50) 1.23 (0.79-1.90) 0.5 0.48 
< secondary  20 (40) 29(60)    
Disclosed status  
Yes 39 (48) 42 (52) 1.12(0.94-1.33) 0.42 0.5 
No 5(31) 11(69)    
Regimens  
same dosing 38 (48) 42 (52) 1.66(0.50-5.65) 0.93 0.3 
different dosing  6 (35) 11 (65)    
ART knowledge 
Yes 34 (48) 37 (52) 1.11(0.87-1.44) 0.35 0.55 
No 10 (38) 16 (62)    
Reported Side Effects 
Yes 17 (53) 15 (47) 0.86(0.64-1.14) 0.74 0.38 
No 27 (42) 38 (58)    
Gender 
Female 39 (51) 37(49) 1.27(1.03-1.56) 3.97 0.04 
Male 5 (24) 16 (76)    
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Table 11: Bivariate analysis using pill count adherence in 3 adherence categories 
  
   Pill count  adherence n=95   
   Adherence Category   
Variable Low 
< 85 
Medium 
85-<95 
High >95 χ² p value 
  
n (%) 
 9 (9) 
n (%) 
 16 (16) 
n (%) 
 70 (74)   
Marital status  
married/cohabiting 6 (12) 9 (18) 34 (70) 1.21* 0.54 
divorced/single/widowed 3 (7) 7 (15) 36 (78)   
Education level  
> secondary  6 (13) 10 (21) 31(76) 2.90* 0.23 
< secondary  3 (6) 6 (12) 39 (82)   
Disclosed status  
Yes 3 (19) 2 (13) 11(68) 2.03 0.36 
No 6 (8) 14 (18) 59 (74)   
Regimens  
same dosing 8 (10) 13 (16) 58(74) 0.26* 0.87 
different dosing  1(6) 3 (19) 12 (75)   
ART knowledge 
Yes 6 (9) 15 (21) 49 (70) 4.04* 0.13 
No 3 (12) 1(4) 21 (84)   
Reported Side Effects 
Yes 4(13) 6 (24) 21 (63) 0.96 0.61 
No 5 (7) 10 (16) 49 (77)   
Sex 
Female 9 (12) 13 (18) 52 (70) 3.19* 0.2 
Male 0 3 (14) 18 (86)   
*Fischer exact test used 
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Table 12: Bivariate analysis using pill count adherence in dichotomous adherence 
categories  
 
  Pill count adherence  n=95    
  Adherence Category    
Variable Suboptimal <95 Optimal  >95 Prevalence Ratio  
(95%CI) 
χ² p value
  
n (%) 
 25 (26) 
n (%) 
 70 (74)    
Marital status  
married/cohabiting 15 (31) 34 (69) 1.24 (0.83-1.84) 0.56 0.45 
divorced/single/widowe
d 10 (22) 36 (78)    
Education level  
> secondary  16 (34) 31(66) 1.45(0.97-2.14) 2.13 0.14 
< secondary  9 (19) 39 (81)    
Disclosed status  
Yes 5 (31) 11 (69) 1.27(0.49-3.30) 0.03 0.75 
No 20 (25) 59 (75)    
Regimens  
same dosing 21 (27) 58 (73) 1.01(083- 1.24) 0.03* 1.00 
different dosing  4 (25) 12 (75)    
ART knowledge 
Yes 21 (30) 49(70) 1.20(0.95-1.51) 1.21* 0.27 
No 4 (16) 21 (84)    
Reported Side Effects 
Yes 15(42) 21(58) 0.86(0.60-1.22) 0.44 0.5 
No 10 (17) 49 (83)    
Gender 
Female 22 (30) 52(70) 1.18(0.97-1.45) 1.29* 0.25 
Male 3(14) 18 (86)    
*Fischer exact test used 
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Table 13: Bivariate analysis of adherence with median distance as the cut off  
 
  Median distance   = 6 km    
  Adherence Category    
Adherence measure distance Suboptimal  <95 
Optimal 
> 95 
Prevalence Ratio 
(95%CI) 
χ² p value 
2 day recall n=93 
 
 
 
n (%) 
6 (6) 
n (%) 
87 (94)  
  
< 6 km 4(8) 45 (92) 1.79  
(0.34 -9.33) 
0.497* 0.39 
> 6 km 2 (5) 42 (95)    
30 day recall adherence n=97 
 
 
 n  (%) 
44 (45) 
n (%) 
53(55)  
  
< 6 km  27 (52) 24 (48) 1.43  
(0.90 – 2.26) 
2.46 0.116 
> 6 km 17(37) 29 (63)    
Pill count  
n = 95 
 
 
 n (%) 
25 (26) 
n(%) 
70 (74)  
  
<  6 km 19 (38) 31(62) 2.85 
(1.24 – 6.50) 
7.353 0.006 
> 6 km 6 (13) 39 (87)    
Composite adherence  
n = 97 
 
 
 n (%) 
35 (36) 
n (%) 
62 (64)  
  
<  6 km 24 (48) 27(52) 1.96  
(1.08 – 3.55) 
5.56 0.018 
> 6km  11 (24) 35 (76)    
*Fischer exact test used 
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Table 14:  Bivariate analysis of adherence with age. 
 
 Mean age  = 36years    
 Adherence Category    
Adherence measure 
age 
band 
Suboptimal 
<95 
Optimal  
>95 
Prevalence 
ratio 
χ² p 
valu
e 
   ( 95%CI)   
2 day recall n=93 
 
 
 n (%) 
 6 (6) 
n (%) 
87(94) 
   
<  36 2 (4) 48 (96) 0.43 
(0.08 - 2.23) 
1.06* 0.26 
> 36 4 (9) 39 (91)    
30 day recall adherence 
n=97 
 
 
 n (%) 
 44 (45) 
n (%) 
 53(55) 
   
<  36 25(50) 25(50) 1.23 
(0.79 -1.92) 
0.88 0.34 
> 36 19 (40) 28 (60)    
Pill count n = 95 
 
 
 n (%) 
 25 (26) 
n (%) 
  70 (74) 
   
<  36 14 (29) 35 (71) 1.19 
(0.60- 2.35) 
0.26 0.6 
> 36 10 (26) 28(74)    
Composite adherence n = 
97 
 
 
 n (%) 
 35(36) 
n (%) 
  62 (64) 
   
<  36 20 (40) 30 (60) 1.25 
(0.73 - 2.14) 
0.67 0.4 
> 36 15(31) 32 (69)    
*Fischer exact test used 
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Table 15: Bivariate analysis of adherence with duration on treatment 
 
    Mean duration on treatment 
= 20 months 
   
    Adherence Category 
 
   
Adherence measure  duration   Suboptimal Optimal Prevalence χ² p 
    < 95% >95% Ratio(95%CI)  value 
2 day recall n=93 
 
 
  n (%) 
  6 (6) 
n (%)  
87 (94) 
   
<   20    2(4) 47 (96) 0.44  
(0.08-2.33) 
0.32* 0.28 
> 20  4 (9) 40 (91)    
30 day recall adherence 
n=97 
 
 
  n (%) 
 44 (45) 
n (%) 
 53(55) 
   
<   20    24 (45) 29 (55) 0.99 
(0.64-1.54) 
0.0003 0.57 
> 20  20 (45) 24 (55)    
Pill count n = 95 
 
 
  n(%) 
  25 (26) 
n (%) 
 70 (74) 
   
<   20    14 (26) 39 (74) 1.01  
(0.51-1.98) 
0.0006 0.98 
> 20  11 (26) 31(74)    
Composite adherence n = 
97 
 
 
  n (%) 
 35(36) 
n (%) 
 62 (64) 
   
<   20    19 (36) 34 (64) 0.98 
(0.57-1.67) 
0.003 0.96 
> 20  16 (36) 28 (64)    
*Fischer exact test used 
 
 
 
 
 
 
 
 
 
 
 
 
 
